Skip to Content

Nifedipine

Class: Dihydropyridines
VA Class: CV200
CAS Number: 21829-25-4
Brands: Adalat CC, Afeditab CR, Nifedical XL, Procardia XL, Procardia

Medically reviewed on Nov 5, 2018

Introduction

Calcium-channel blocking agent; dihydropyridine derivative.284 307 342 343

Uses for Nifedipine

Angina

Management of Prinzmetal variant angina and chronic stable angina.a

A drug of choice for the management of Prinzmetal variant angina (used alone or in combination with nitrates).1100

β-Blockers are recommended as the anti-ischemic drugs of choice in most patients with chronic stable angina; calcium-channel blockers may be substituted or added in patients who do not tolerate or respond adequately to β-blockers.1101

Also has been used in patients with unstable angina; however, nondihydropyridine calcium-channel blockers (e.g., diltiazem, verapamil) generally recommended.1100

The potential risks of short-acting (conventional, immediate-release) nifedipine should be considered.242

Hypertension

Management of hypertension, alone or in combination with other classes of antihypertensive agents.126 309 342 343 344 345 348 351 1200

Only extended-release formulations currently are recommended for management of hypertension.121 126 178 181 183 184 191 192 193 197 201 202 204 205 206 207 208 209 210 211 212 213 225 226 264 309 342 344 348 1200 (See Cautions.)

Calcium-channel blockers are recommended as one of several preferred agents for the initial management of hypertension according to current evidence-based hypertension guidelines; other preferred options include ACE inhibitors, angiotensin II receptor antagonists, and thiazide diuretics.501 502 503 504 1200 While there may be individual differences with respect to recommendations for initial drug selection and use in specific patient populations, current evidence indicates that these antihypertensive drug classes all generally produce comparable effects on overall mortality and cardiovascular, cerebrovascular, and renal outcomes.501 502 503 504 1200 1213

Individualize choice of therapy; consider patient characteristics (e.g., age, ethnicity/race, comorbidities, cardiovascular risk) as well as drug-related factors (e.g., ease of administration, availability, adverse effects, cost).501 502 503 504 515 1200 1201

A 2017 ACC/AHA multidisciplinary hypertension guideline classifies BP in adults into 4 categories: normal, elevated, stage 1 hypertension, and stage 2 hypertension.1200 (See Table 1.)

Source: Whelton PK, Carey RM, Aronow WS et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:e13-115.

Individuals with SBP and DBP in 2 different categories (e.g., elevated SBP and normal DBP) should be designated as being in the higher BP category (i.e., elevated BP).

Table 1. ACC/AHA BP Classification in Adults1200

Category

SBP (mm Hg)

DBP (mm Hg)

Normal

<120

and

<80

Elevated

120–129

and

<80

Hypertension, Stage 1

130–139

or

80–89

Hypertension, Stage 2

≥140

or

≥90

The goal of hypertension management and prevention is to achieve and maintain optimal control of BP.1200 However, the BP thresholds used to define hypertension, the optimum BP threshold at which to initiate antihypertensive drug therapy, and the ideal target BP values remain controversial.501 503 504 505 506 507 508 515 523 526 530 1200 1201 1207 1209 1222 1223 1229

The 2017 ACC/AHA hypertension guideline generally recommends a target BP goal (i.e., BP to achieve with drug therapy and/or nonpharmacologic intervention) <130/80 mm Hg in all adults regardless of comorbidities or level of atherosclerotic cardiovascular disease (ASCVD) risk.1200 In addition, an SBP goal of <130 mm Hg generally is recommended for noninstitutionalized ambulatory patients ≥65 years of age with an average SBP of ≥130 mm Hg.1200 These BP goals are based upon clinical studies demonstrating continuing reduction of cardiovascular risk at progressively lower levels of SBP.1200 1202 1210

Previous hypertension guidelines generally have based target BP goals on age and comorbidities.501 504 536 Guidelines such as those issued by the JNC 8 expert panel generally have targeted a BP goal of <140/90 mm Hg regardless of cardiovascular risk, and have used higher BP thresholds and target BPs in elderly patients501 504 compared with those recommended by the 2017 ACC/AHA hypertension guideline.1200

Some clinicians continue to support previous target BPs recommended by JNC 8 due to concerns about the lack of generalizability of data from some clinical trials (e.g., SPRINT study) used to support the 2017 ACC/AHA hypertension guideline and potential harms (e.g., adverse drug effects, costs of therapy) versus benefits of BP lowering in patients at lower risk of cardiovascular disease.1222 1223 1224 1229

Consider potential benefits of hypertension management and drug cost, adverse effects, and risks associated with the use of multiple antihypertensive drugs when deciding a patient’s BP treatment goal.1200 1220 1229

For decisions regarding when to initiate drug therapy (BP threshold), the 2017 ACC/AHA hypertension guideline incorporates underlying cardiovascular risk factors.1200 1207 ASCVD risk assessment recommended by ACC/AHA for all adults with hypertension.1200

ACC/AHA currently recommend initiation of antihypertensive drug therapy in addition to lifestyle/behavioral modifications at an SBP ≥140 mm Hg or DBP ≥90 mm Hg in adults who have no history of cardiovascular disease (i.e., primary prevention) and a low ASCVD risk (10-year risk <10%).1200

For secondary prevention in adults with known cardiovascular disease or for primary prevention in those at higher risk for ASCVD (10-year risk ≥10%), ACC/AHA recommend initiation of antihypertensive drug therapy at an average SBP ≥130 mm Hg or an average DBP ≥80 mm Hg.1200

Adults with hypertension and diabetes mellitus, chronic kidney disease (CKD), or age ≥65 years of age are assumed to be at high risk for cardiovascular disease; ACC/AHA state that such patients should have antihypertensive drug therapy initiated at a BP ≥130/80 mm Hg.1200 Individualize drug therapy in patients with hypertension and underlying cardiovascular or other risk factors.502 1200

In stage 1 hypertension, experts state that it is reasonable to initiate drug therapy using the stepped-care approach in which one drug is initiated and titrated and other drugs are added sequentially to achieve the target BP.1200 Initiation of antihypertensive therapy with 2 first-line agents from different pharmacologic classes recommended in adults with stage 2 hypertension and average BP >20/10 mm Hg above BP goal.1200

Calcium-channel blockers may be preferred in hypertensive patients with certain coexisting conditions (e.g., ischemic heart disease)171 185 187 192 198 523 and in geriatric patients, including those with isolated systolic hypertension.181 183 220 221 222 227 502 510

Black hypertensive patients generally respond better to monotherapy with calcium-channel blockers or thiazide diuretics than to other antihypertensive drug classes (e.g., ACE inhibitors, angiotensin II receptor antagonists).501 504 1200 However, the combination of an ACE inhibitor or an angiotensin II receptor antagonist with a calcium-channel blocker or thiazide diuretic produces similar BP lowering in black patients as in other racial groups.1200

Nifedipine is not recommended for management of hypertensive crises.283 284 295 307 338 339 340 341

Nifedipine is recommended by ACOG and other experts as an appropriate drug of choice in pregnant women who require antihypertensive therapy.388 540

Raynaud’s Phenomenon

Drug of choice for the management of Raynaud’s phenomenon,144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 296 297 298 305 306 preferably administered as extended-release formulations.296 297 305 306

Preterm Labor

Has been used in selected women to inhibit uterine contractions in preterm labor (tocolysis) and prolong gestation when beneficial.290 291 292 293 294 389

ACOG states that because of conflicting results, there is no clear first-line tocolytic agent;389 data from randomized, controlled studies suggest calcium-channel blockers (principally nifedipine) may be more effective than, and preferable to, other agents (e.g., magnesium sulfate, β-adrenergic agonists).390

Main benefit currently derived from tocolytic therapy may be to forestall labor providing time for patients to receive corticosteroids to increase fetal lung maturation and/or be transferred to other (e.g., tertiary-care) facilities; any other potential benefits of prolonging pregnancy are unclear.290 291 293 294 389 390 419 420 421

Acute MI

Used in the early treatment and secondary prevention of acute MI; an effective anti-ischemic agent, but mortality benefit not demonstrated.266 527 1100

Calcium-channel blockers generally are used for their anti-ischemic and BP-reducing properties in the MI setting, and only when β-blockers (which have been shown to reduce mortality after MI) are ineffective, not tolerated, or contraindicated.527 702 1100

Experts state that calcium-channel blockers may be used to relieve ischemic symptoms, lower BP, or control rapid ventricular response rate associated with atrial fibrillation in patients with ST-segment-elevation MI (STEMI) who are intolerant to β-blockers.527

Experts recommend a nondihydropyridine calcium-channel blocker for ongoing or recurrent ischemia in patients with non-ST-segment-elevation MI (NSTEMI) who have a contraindication to β-blockers and who do not have clinically important left ventricular dysfunction, increased risk of cardiogenic shock, or AV block.1100

Use of immediate-release nifedipine generally contraindicated because of possible hypotension and reflex sympathetic activation.527 1100

Nifedipine Dosage and Administration

General

BP Monitoring and Treatment Goals

  • Monitor BP regularly (i.e., monthly) during therapy and adjust dosage of the antihypertensive drug until BP controlled.1200

  • If unacceptable adverse effects occur, discontinue drug and initiate another antihypertensive agent from a different pharmacologic class.1200 1216

  • If adequate BP response not achieved with a single antihypertensive agent, either increase dosage of single drug or add a second drug with demonstrated benefit and preferably a complementary mechanism of action (e.g., ACE inhibitor, angiotensin II receptor antagonist, thiazide diuretic).1200 1216 Many patients will require at least 2 drugs from different pharmacologic classes to achieve BP goal; if goal BP still not achieved, add a third drug.1200 1216

Administration

Oral Administration

Conventional Capsules

Administer capsules orally 3 times daily.284

Swallow capsules whole.284

Extended-release Tablets

Administer orally once daily.126 342

Extended-release tablets should be swallowed intact and should not be chewed, crushed, or broken.126 342

Manufacturer recommends that Adalat CC be administered on an empty stomach.342

The shell of the extended-release tablet does not dissolve and may be passed in the stool.342 343

Whenever extended-release tablets are dispensed or administered, care should be taken to ensure that the extended-release dosage form actually was prescribed.126

Dosage of extended-release nifedipine tablets should be decreased gradually with close clinical supervision when discontinuance of the drug is required.126 342

Dosage

Manufacturer states that two 30-mg Adalat CC extended-release tablets may be interchanged with one 60-mg Adalat CC extended-release tablet; however, three 30-mg Adalat CC extended-release tablets should not be considered interchangeable with one 90-mg Adalat CC extended-release tablet.342

Pediatric Patients

Hypertension
Extended-release Tablets
Oral

Initially, 0.2–0.5 mg/kg daily given in 1 dose or 2 divided doses recommended by some experts.1150 Initiate drug at the low end of the dosage range; may increase dosage every 2–4 weeks until BP controlled, maximum dosage reached (3 mg/kg [up to 120 mg] daily, given in 1 or 2 divided doses), or adverse effects occur.1150

Adults

Angina
Conventional Capsules
Oral

Initially, 10 mg 3 times daily.284 307

Increase dosage gradually at 7- to 14-day intervals until optimum control of angina is obtained.a

May increase more rapidly to 90 mg daily in increments of 30 mg daily over a 3-day period if symptoms so warrant and patient’s tolerance and response to therapy are frequently assessed.284 307

In hospitalized patients who are closely monitored, dosage may be increased in 10-mg increments at 4- to 6-hour intervals, as necessary to control pain and arrhythmias caused by ischemia.284 307 Single doses usually should not exceed 30 mg.284 307

Some experts state usual maintenance dosage is 10–20 mg 3 times daily.a In some patients, especially those with evidence of coronary artery spasm, increased dosages of 20–30 mg 3 or 4 times daily and rarely, more than 120 mg daily may be necessary.a

Extended-release Tablets
Oral

Initially, 30 or 60 mg once daily.126

Increase dosage gradually at 7- to 14-day intervals until optimum control of angina is obtained.a

Dosage may be increased more rapidly to 90 mg daily in increments of 30 mg daily after steady state is achieved (usually achieved on the second day of therapy with a given dose) if symptoms so warrant and patient’s tolerance and response are frequently assessed.126

In some patients, especially those with evidence of coronary artery spasm, higher dosages may be necessary.a However, experience with antianginal dosages exceeding 90 mg once daily as extended-release tablets is limited and should be employed with caution and only when clinically necessary.126

Extended-release tablets can be substituted for the conventional capsules at the nearest equivalent total daily dose.126

Hypertension
Conventional Capsules
Oral

Conventional capsules not recommended for use in the management of hypertension242 284 307 344 345 because of concerns about potential cardiovascular risks.240 241 242 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 266 284 307 344 345 346 347 348

Extended-release Tablets
Oral

Initially, 30 or 60 mg once daily.126

Increase dosage gradually at 7- to 14-day intervals until optimum control of BP is obtained.126 342 a

Dosage may be increased more rapidly, if symptoms so warrant and the patient’s tolerance and response to therapy are frequently assessed.126

Usual maintenance dosage is 30–90 mg once daily.1200

If unacceptable adverse effects occur, discontinue the drug and initiate another hypertensive agent from a different pharmacologic class.1200 1216

Prescribing Limits

Pediatric Patients

Hypertension
Oral

Extended-release tablets: Maximum 3 mg/kg (up to 120 mg) daily.1150

Adults

Angina
Oral

Conventional liquid-filled capsules: Maximum 30 mg as a single dose.284 307 Maximum 180 mg daily.284

Extended-release tablets: Maximum 120 mg daily.126

Hypertension
Oral

Extended-release tablets: Maximum 90 mg (Adalat CC) or 120 mg (Procardia XL) once daily.126 342

Cautions for Nifedipine

Contraindications

  • Known hypersensitivity to nifedipine or any ingredient in the formulation.126 284 307 342 343

Warnings/Precautions

Warnings

Excessive Hypotension

Risk of excessive, poorly tolerated hypotension in patients being treated for angina; usually occurs during initial dosage titration or subsequent upward titration and may be more likely in patients receiving concomitant β-blocker.114 126 129 284 286 307 Carefully monitor BP, especially during therapy initiation, titration, or dosage increase.126 284 342 a

Cardiovascular Effects with Conventional Preparations

Conventional (immediate-release) nifedipine formulations generally are contraindicated in the routine management of acute MI because of negative inotropic effects and reflex sympathetic activation, tachycardia, and hypotension associated with its use.242 284 307 527 Do not administer within first 1–2 weeks after MI and avoid in acute coronary syndrome when infarction may be imminent.284 307

Risk of profound hypotension, cerebrovascular ischemia or stroke, myocardial ischemia or infarction, and/or death with use of conventional preparations for management of hypertensive crises;119 283 284 288 295 300 302 303 304 307 308 similar effects reported in patients receiving such preparations for angina or pulmonary hypertension.283 286 287 310 Do not use short-acting preparations for acute BP reduction or for chronic hypertension management.284 307

Increased Angina and/or Acute MI

Rarely, increased frequency, duration, and/or severity of angina or acute MI, particularly in patients with severe obstructive CAD, upon initiation or dosage increase of calcium-channel blockers.126 284 342

β-Blocker Withdrawal

Possible increased angina in patients recently withdrawn from β-blockers after nifedipine initiation.126 284 342 Taper dosage of β-blockers before initiation of nifedipine.126 284 342 (See Interactions.)

Heart Failure

Risk of heart failure, especially in those receiving concomitant β-blockers, particularly in patients with aortic stenosis.126 284 342

Sensitivity Reactions

Rash, dermatitis (including exfoliative dermatitis), erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, photosensitivity reactions, pruritus, urticaria, allergic hepatitis, and angioedema, principally oropharyngeal edema and occasionally breathing difficulty, reported.126 284 342

General Precautions

Peripheral Edema

Consider possibility of deterioration in left ventricular function, especially in patients with heart failure, if peripheral edema develops.126 284 342

GI Disorders

Use extended-release tablets with caution in patients with preexisting GI narrowing; obstruction may occur.126

Specific Populations

Pregnancy

Category C.126 284 342

Lactation

Distributed into milk.165 342 Discontinue nursing or the drug.342

Pediatric Use

Safety and efficacy remain to be fully established in children;126 284 however, some experts have recommended dosages for hypertension based on clinical experience.1150

Geriatric Use

Insufficient experience in patients ≥65 years of age to determine whether geriatric patients respond differently than younger adults.284 342 Select dosage with caution.284 342

Renal Impairment

Use Adalat CC extended-release nifedipine tablets with caution in patients with renal impairment due to the possibility of altered absorption of the drug.342

Common Adverse Effects

Dizziness, lightheadedness, giddiness, flushing, heat sensation, headache, tremor, nervousness, mood changes, weakness, fatigue, asthenia, muscle cramps, nausea, heartburn, peripheral edema, dyspnea, cough, wheezing, nasal congestion, sore throat.126 284 342

Interactions for Nifedipine

Metabolized by CYP isoenzymes, principally CYP3A.342 May inhibit CYP3A; does not appear to affect CYP2D6.342

Specific Drugs and Food

Drug or Food

Interaction

Comments

β-Adrenergic blocking agents

Increased risk of severe hypotension, exacerbation of angina, heart failure, and arrhythmiaa

Monitor patient and adjust nifedipine dosage as needed;342 gradually reduce β-blocker dosage instead of abruptly withdrawing126 284 342 a

Acarbose

Possible loss of glycemic control342

Monitor glucose concentrations and adjust nifedipine dosage as needed342

Alcohol

Increased nifedipine bioavailability236

Anticoagulants (e.g., coumarins)

Possible increased PT126 284 342

Antifungals, azoles (fluconazole, itraconazole, ketoconazole)

Possible increased plasma nifedipine concentrations342

Monitor BP and adjust nifedipine dosage as needed342

Antiretroviral agents (HIV protease inhibitors [amprenavir, atazanavir, fosamprenavir, indinavir, nelfinavir, ritonavir], nonnucleoside reverse transcriptase inhibitors [delavirdine])

Possible increased plasma nifedipine concentrations342

Use concomitantly with caution; monitor patient carefully342

Antituberculosis agents (rifabutin, rifampin)

Possible decreased plasma nifedipine concentrations342 401

Adjust nifedipine dosage as needed342

Benazepril

Possible attenuation of tachycardic effect of nifedipine342

Candesartan

Pharmacokinetic interaction unlikely342

Carbamazepine

Possible decreased plasma nifedipine concentrations342

Adjust nifedipine dosage as needed342

Clopidogrel

Pharmacokinetic interaction unlikely342

Digoxin

Increased serum digoxin concentration106 107 126

Monitor serum digoxin concentrations when nifedipine therapy is initiated, discontinued, or dosage is adjusted in patients receiving digoxin108 126 284 307 342

Monitor for signs and symptoms of digoxin toxicity and reduce dosage if necessary101 106 126 284 307

Diltiazem

Possible increased plasma nifedipine concentrations342 399

Dolasetron

Pharmacokinetic interaction unlikely342

Erythromycin

Possible increased plasma nifedipine concentrations342

Monitor BP and adjust nifedipine dosage as needed342

Fentanyl

Potential for severe hypotensiona

If patient’s condition permits, temporarily withhold nifedipine for at least 36 hours before surgery if use of high-dose fentanyl is contemplated126 284 342

Flecainide

Insufficient clinical experience to recommend concomitant use342

Grapefruit juice

Increased nifedipine bioavailability284 311 314 323 324 342 371 372 373

Avoid concomitant use;284 314 342 371 372 373 discontinue grapefruit juice consumption at least 3 days prior to initiating nifedipine therapy342

Histamine H2-receptor antagonists (cimetidine, ranitidine)

Decreased clearance and increased plasma nifedipine concentrations and AUC with concomitant cimetidine or (to lesser extent) ranitidine115 116 125 284 342

Cautiously titrate nifedipine dosage in patients receiving cimetidine; may need to reduce nifedipine dosage in patients stabilized on the drug if cimetidine therapy is initiated115 125 284 342

Hypotensive agents (captopril, doxazosin, hydralazine, methyldopa)

Increased incidence of severe hypotensiona

Observe patient closely when nifedipine is added to existing antihypertensive regimen, especially during initial titration or upward adjustment of nifedipine dosage126 284 342

Irbesartan

Pharmacokinetic interaction unlikely342

Metformin

Possible increased absorption of metformin342

Nefazodone

Possible increased plasma nifedipine concentrations342

Monitor BP and adjust nifedipine dosage as needed342

Omeprazole

Pharmacokinetic interaction unlikely342

Pantoprazole

Pharmacokinetic interaction unlikely342

Phenobarbital

Possible decreased plasma nifedipine concentrations342

Adjust nifedipine dosage as needed342

Phenytoin

Possible decreased phenytoin metabolism;166 167 possible decreased plasma nifedipine concentrations342

Monitor plasma phenytoin concentrations when nifedipine is initiated or discontinued;166 monitor BP and adjust nifedipine dosage as needed342

Quinidine

Possible increased plasma nifedipine concentrations;342 397 possible decreased serum quinidine concentrations284 307 332 333 334 335 336 337 396 397

Monitor heart rate and adjust nifedipine dosage as needed;342 monitor serum quinidine concentrations whenever nifedipine is initiated or discontinued; adjust quinidine dosage accordingly333 334 335 336 337

Quinupristin and dalfopristin

Possible increased plasma nifedipine concentrations342 378

Monitor BP and adjust nifedipine dosage as needed342

Sirolimus

Pharmacokinetic interaction unlikely342

St. John’s wort

Possible decreased plasma nifedipine concentrations342

Adjust nifedipine dosage as needed342

Tacrolimus

Possible increased plasma tacrolimus concentrations342

Monitor tacrolimus blood concentrations and adjust tacrolimus dosage as needed342

Tirofiban

Pharmacokinetic interaction unlikely342

Valproic acid

Possible increased plasma nifedipine concentrations342

Monitor BP and adjust nifedipine dosage as needed342

Verapamil

Possible increased plasma nifedipine concentrations342

Monitor BP and adjust nifedipine dosage as needed342

Nifedipine Pharmacokinetics

Absorption

Bioavailability

Following oral administration of conventional capsules, approximately 90% of a dose is absorbed with peak serum concentrations usually attained within 0.5–2 hours.a

Oral bioavailability of extended-release tablets is approximately 75–89% of that achieved with same doses as conventional capsules.126 130 342

Peak plasma concentrations for extended-release tablets are attained within about 2.5–6 hours.130 342

Food

Food decreases the rate but not extent of absorption from conventional capsules.140

Food can increase the early rate of GI absorption of extended-release tablets but does not affect overall bioavailability.126 342

Special Populations

Bioavailability is increased in patients with liver cirrhosis126 132 133 284 307 342 and may be particularly increased in those with portacaval shunts.132

Following oral administration of extended-release tablets (Adalat CC), , absorption of nifedipine may be altered in patients with renal impairment.342

Substantial reductions in GI retention time for prolonged periods (e.g., in patients with short-bowel syndrome) can result in decreased absorption from extended-release tablets.126

Increased mean peak plasma concentrations and average plasma concentrations compared with those in younger adults have been reported in healthy subjects >60 years of age receiving Adalat CC extended-release tablets.342

Distribution

Extent

Nifedipine is distributed into milk.165

Plasma Protein Binding

Approximately 92–98%.126 284

Special Populations

Plasma protein binding may be decreased in patients with renal126 133 139 284 307 342 or hepatic126 132 133 284 307 342 impairment.

Elimination

Metabolism

Extensively metabolized in the liver by CYP isoenzymes, including CYP3A, to highly water soluble, inactive metabolites.126 284 342 a

Elimination Route

Metabolites excreted in urine (60–80%) and feces (possibly via biliary elimination).126 342 a

Half-life

2 hours (conventional capsules); 7 hours (Adalat CC extended-release tablets).126 284 342 a

Special Populations

Elimination may be altered in patients with hepatic impairment.126 132 133 284 307 342 Elimination half-life of 7 hours reported in patients with cirrhosis.132 133

Following IV administration, decreased total body clearance in geriatric individuals compared with that in young adults .342

Stability

Storage

Oral

Capsules

Tight, light resistant containers at 15–25°C; protect from light and moisture.284

Extended-release Tablets

Tight, light resistant containers at <30°C; protect from light and moisture.126 342

Actions

  • Inhibits transmembrane influx of extracellular calcium ions across the membranes of myocardial cells and vascular smooth muscle cells, without changing serum calcium concentrations.126 284 342

  • Peripheral arterial vasodilator; acts directly on vascular smooth muscle causing reduction in peripheral vascular resistance (afterload) and BP.126 284 342

Advice to Patients

  • Importance of swallowing extended-release tablets whole; do not chew, crush, or break.126 342

  • Importance of advising patients receiving extended-release tablets that tablet core may be excreted in stools without affecting drug efficacy.126

  • Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses.126 284 342

  • Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.126 284 342

  • Importance of informing patients of other important precautionary information.126 284 342 (See Cautions.)

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

NIFEdipine

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Capsules, liquid-filled

10 mg*

NIFEdipine Capsules

Procardia

Pfizer

20 mg*

NIFEdipine Capsules

Tablets, extended-release, film-coated

30 mg*

Adalat CC

Bayer

Afeditab CR

Watson

Nifedical XL

Teva

NIFEdipine ER

Procardia XL

Pfizer

60 mg*

Adalat CC

Bayer

Afeditab CR

Watson

Nifedical XL

Teva

NIFEdipine ER

Procardia XL

Pfizer

90 mg*

Adalat CC

Bayer

NIFEdipine ER

Procardia XL

Pfizer

AHFS DI Essentials™. © Copyright 2018, Selected Revisions November 5, 2018. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

Only references cited for selected revisions after 1984 are available electronically.

100. Kleinbloesem CH, van Brummelen P, Woittiez AJ et al. Influence of haemodialysis on the pharmacokinetics and haemodynamic effects of nifedipine during continuous intravenous infusion. Clin Pharmacokinet. 1986; 11:316-22. http://www.ncbi.nlm.nih.gov/pubmed/3757391?dopt=AbstractPlus

101. Hansten PD. Drug interactions. 5th ed. Philadelphia: Lea & Febiger; 1985; 279-85.

102. Pedersen KE, Dorph-Pedersen A, Hvidt S et al. Effect of nifedipine on digoxin kinetics in healthy subjects. Clin Pharmacol Ther. 1982; 32:562-5. http://www.ncbi.nlm.nih.gov/pubmed/7127997?dopt=AbstractPlus

103. Schwartz JB, Migliore PJ. Effect of nifedipine on serum digoxin concentration and renal digoxin clearance. Clin Pharmacol Ther. 1984; 36:19-24. http://www.ncbi.nlm.nih.gov/pubmed/6734045?dopt=AbstractPlus

104. Schwartz JB, Raizner A, Akers S. The effect of nifedipine on serum digoxin concentrations in patients. Am Heart J. 1984; 107:669-73. http://www.ncbi.nlm.nih.gov/pubmed/6702561?dopt=AbstractPlus

105. Garty M, Shamir E, Ilfeld D et al. Noninteraction of digoxin and nifedipine in cardiac patients. J Clin Pharmacol. 1986; 26:304-5. http://www.ncbi.nlm.nih.gov/pubmed/3700685?dopt=AbstractPlus

106. Belz GG, Doering W, Munkes R et al. Interaction between digoxin and calcium antagonists and antiarrhythmic drugs. Clin Pharmacol Ther. 1983; 33:410-7. http://www.ncbi.nlm.nih.gov/pubmed/6831819?dopt=AbstractPlus

107. Kirch W, Hutt HJ, Dylewicz P et al. Dose-dependence of the nifedipine-digoxin interaction. Clin Pharmacol Ther. 1986; 39:35-9. http://www.ncbi.nlm.nih.gov/pubmed/3943268?dopt=AbstractPlus

108. Pfizer Laboratories. Procardia (nifedipine) capsules prescribing information. In: Huff BB, ed. Physicians’ desk reference. 40th ed. Oradell, NJ: Medical Economics Company Inc; 1986:1423-4.

109. Houston MC. Treatment of hypertensive urgencies and emergencies with nifedipine. Am Heart J. 1986; 111:963-9. http://www.ncbi.nlm.nih.gov/pubmed/3518379?dopt=AbstractPlus

110. Haft JI, Litterer WE III. Chewing nifedipine to rapidly treat hypertension. Arch Intern Med. 1984; 144:1357-9.

111. Bertel O, Conen D, Radu EW et al. Nifedipine in hypertensive emergencies. BMJ. 1983; 286:19-21. http://www.ncbi.nlm.nih.gov/pubmed/6401442?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1546618&blobtype=pdf

112. Huysmans FTM, Sluiter HE, Thien TA et al. Acute treatment of hypertensive crisis with nifedipine. Br J Clin Pharmacol. 1983; 16:725-7. http://www.ncbi.nlm.nih.gov/pubmed/6661359?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1428348&blobtype=pdf

113. Lacche A, Basaglia P. Hypertensive emergencies: effects of therapy by nifedipine administered sublingually. Curr Ther Res. 1983; 34:879-87.

114. Pfizer Laboratories Division. Procardia (nifedipine) capsules prescribing information dated Feb 1993. In: Physicians’ desk reference. 48th ed. Montvale, NJ: Medical Economics Company Inc; 1994; 1795-6.

115. Mangini RJ, ed. Drug interaction facts. St. Louis: JB Lippincott Co; 1985(Oct):405a.

116. Kirch W, Ohnhaus EE, Hoensch H et al. Ranitidine increases bioavailability of nifedipine. Clin Pharmacol Ther. 1985; 37:204.

117. Adler AG, Leahy JJ, Cressman MD. Management of perioperative hypertension using sublingual nifedipine: experience in elderly patients undergoing eye surgery. Arch Intern Med. 1986; 146:1927-30. http://www.ncbi.nlm.nih.gov/pubmed/3767537?dopt=AbstractPlus

118. Houston MC. The comparative efficacy of clonidine hydrochloride and nifedipine in the treatment of hypertensive crises. Am Heart J. 1988; 115:152-9. http://www.ncbi.nlm.nih.gov/pubmed/3276107?dopt=AbstractPlus

119. Wachter RM. Symptomatic hypotension induced by nifedipine in the acute treatment of severe hypertension. Arch Intern Med. 1987; 147:556-8. http://www.ncbi.nlm.nih.gov/pubmed/3827433?dopt=AbstractPlus

120. Frishman WH, Charlap S. Nifedipine in the treatment of systemic hypertension. Arch Intern Med. 1984; 144:2335-6. http://www.ncbi.nlm.nih.gov/pubmed/6508440?dopt=AbstractPlus

121. Ferlinz J. Nifedipine in myocardial ischemia, systemic hypertension, and other cardiovascular disorders. Ann Intern Med. 1986; 105:714-29. http://www.ncbi.nlm.nih.gov/pubmed/3532894?dopt=AbstractPlus

122. Jennings AA, Jee LD, Smith JA et al. Acute effect of nifedipine on blood pressure and left ventricular ejection fraction in severely hypertensive outpatients: predictive effects of acute therapy and prolonged efficacy when added to existing therapy. Am Heart J. 1986; 111:557-63. http://www.ncbi.nlm.nih.gov/pubmed/2869672?dopt=AbstractPlus

123. Anon. Drugs for hypertensive emergencies. Med Lett Drug Ther. 1987; 29:18-20.

124. Erbel R, Brand G, Meyer J et al. Emergency treatment of hypertensive crisis with sublingual nifedipine. Postgrad Med J. 1983; 59(Suppl 3):134-6. http://www.ncbi.nlm.nih.gov/pubmed/6647199?dopt=AbstractPlus

125. Kirch W, Janisch HD, Heidemann H et al. Einfluss von Cimetidin und Ranitidin auf Pharmakokinetik und antihypertensiven Effekt von Nifedipin. (German; with English abstract.) Dtsch Med Wochenschr. 1983; 108:1757-61.

126. Pfizer. Procardia XL (nifedipine extended release tablets) prescribing information. New York, NY; 2003 Aug.

127. Swanson DR, Barclay BL, Wong PSL et al. Nifedipine gastrointestinal therapeutic system. Am J Med. 1987; 83(Suppl 6B):3-9.

128. Theeuwes F. Elementary osmotic pump. J Pharm Sci. 1975; 64:1987-91. http://www.ncbi.nlm.nih.gov/pubmed/1510?dopt=AbstractPlus

129. Pfizer Laboratories. Procardia XL product information form. New York; 1989 Sept.

130. Chung M, Reitberg DP, Gaffney M et al. Clinical pharmacokinetics of nifedipine gastrointestinal therapeutic system: a controlled-release formulation of nifedipine. Am J Med. 1987; 83(Suppl 6B):10-4. http://www.ncbi.nlm.nih.gov/pubmed/3503594?dopt=AbstractPlus

131. Ueno K, Kawashima S, Uemoto K et al. Effect of food on nifedipine sustained-release preparation. DICP. 1989; 23:662-5. http://www.ncbi.nlm.nih.gov/pubmed/2800577?dopt=AbstractPlus

132. Kleinbloesem CH, van Harten J, Wilson JPH et al. Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration. Clin Pharmacol Ther. 1986; 40:21-8. http://www.ncbi.nlm.nih.gov/pubmed/3720176?dopt=AbstractPlus

133. Echizen H, Eichelbaum M. Clinical pharmacokinetics of verapamil, nifedipine and diltiazem. Clin Pharmacokinet. 1986; 11:425-49. http://www.ncbi.nlm.nih.gov/pubmed/3542336?dopt=AbstractPlus

134. McAllister RG Jr. Kinetics and dynamics of nifedipine after oral and sublingual doses. Am J Med. 1986; 81(Suppl 6A):2-5. http://www.ncbi.nlm.nih.gov/pubmed/3799661?dopt=AbstractPlus

135. van Harten J, Burggraaf K, Danhoe M et al. Negligible sublingual absorption of nifedipine. Lancet. 1987; 2:1363-4. http://www.ncbi.nlm.nih.gov/pubmed/2890954?dopt=AbstractPlus

136. McAllister RG Jr, Hamann SR, Blouin RA. Pharmacokinetics of calcium-entry blockers. Am J Cardiol. 1985; 55:30-40B.

137. Raemsch KD, Sommer J. Pharmacokinetics and metabolism of nifedipine. Hypertension. 1983; 5:II-18-24. http://www.ncbi.nlm.nih.gov/pubmed/6862586?dopt=AbstractPlus

138. Foster TS, Hamann SR, Richards VR et al. Nifedipine kinetics and bioavailability after single intravenous and oral doses in normal subjects. J Clin Pharmacol. 1983; 23:161-70. http://www.ncbi.nlm.nih.gov/pubmed/6863580?dopt=AbstractPlus

139. Kleinbloesem CH, van Brummelen P, van Harten J et al. Nifedipine: influence of renal function on pharmacokinetic/hemodynamic relationship. Clin Pharmacol. 1985; 37:563-74.

140. Reitberg DP, Love SJ, Quercia GT et al. Effect of food on nifedipine pharmacokinetics. Clin Pharmacol Ther. 1987; 42:72-5. http://www.ncbi.nlm.nih.gov/pubmed/3595068?dopt=AbstractPlus

142. The Expert Panel. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch Intern Med. 1988; 148:36-69. http://www.ncbi.nlm.nih.gov/pubmed/3422148?dopt=AbstractPlus

144. Gjorup T, Kelbaek H, Hartling OJ et al. Controlled double-blind trial of the clinical effect of nifedipine in the treatment of idiopathic Raynaud’s phenomenon. Am Heart J. 1986; 111:742-5. http://www.ncbi.nlm.nih.gov/pubmed/3513504?dopt=AbstractPlus

145. Smith CD, McKendry RJR. Controlled trial of nifedipine in the treatment of Raynaud’s phenomenon. Lancet. 1982; 2:1299-301. http://www.ncbi.nlm.nih.gov/pubmed/6128596?dopt=AbstractPlus

146. Ettinger WH, Wise RA, Schaffhauser D et al. Controlled double-blind trial of dazoxiben and nifedipine in the treatment of Raynaud’s phenomenon. Am J Med. 1984; 77:451-6. http://www.ncbi.nlm.nih.gov/pubmed/6540986?dopt=AbstractPlus

147. Roath S. Managing Raynaud’s phenomenon. BMJ. 1986; 293:88-9. http://www.ncbi.nlm.nih.gov/pubmed/3089429?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1340833&blobtype=pdf

148. Rademaker M, Cooke ED, Almond NE et al. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud’s phenomenon in patients with systemic sclerosis: a double-blind randomised study. BMJ. 1989; 298:561-4. http://www.ncbi.nlm.nih.gov/pubmed/2467711?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1835951&blobtype=pdf

149. Kaya IS, Senses DA, Dilmen U. Nifedipine in the treatment of Raynaud’s disease in childhood. Lancet. 1989; 1:1136. http://www.ncbi.nlm.nih.gov/pubmed/2566072?dopt=AbstractPlus

150. Russell A, Kappagoda T. Reactive hyperemia in patients with Raynaud’s phenomenon. J Rheumatol. 1988; 15:1653-7. http://www.ncbi.nlm.nih.gov/pubmed/3236299?dopt=AbstractPlus

151. Miller FW, Love LA. Prevention of predictable Raynaud’s phenomenon by sublingual nifedipine. N Engl J Med. 1987; 317:1476. http://www.ncbi.nlm.nih.gov/pubmed/3683482?dopt=AbstractPlus

152. Costantini A, Martelli E, Bavera P et al. Slow release nifedipine in the treatment of Raynaud’s phenomenon. Int Angiol. 1987; 6:359-63. http://www.ncbi.nlm.nih.gov/pubmed/3330116?dopt=AbstractPlus

153. Lewis P, Psaila JV, Morgan RH et al. Nifedipine in patients with Raynaud’s syndrome—effects on radial artery blood flow. Eur Heart J. 1987; 8(Suppl K):83-6. http://www.ncbi.nlm.nih.gov/pubmed/3450524?dopt=AbstractPlus

154. Wollersheim H, Thien T, van ’t Laar A. Nifedipine in primary Raynaud’s phenomenon and in scleroderma: oral versus sublingual hemodynamic effects. J Clin Pharmacol. 1987; 27:907-13. http://www.ncbi.nlm.nih.gov/pubmed/3429697?dopt=AbstractPlus

155. Meyrick TRH, Rademaker M, Grimes SM et al. Nifedipine in the treatment of Raynaud’s phenomenon in patients with systemic sclerosis. Br J Dermatol. 1987; 117:237-41. http://www.ncbi.nlm.nih.gov/pubmed/3307894?dopt=AbstractPlus

156. Nilsson H, Jonason T, Leppert J et al. The effect of the calcium-entry blocker nifedipine on cold-induced digital vasospasm; a double-blind crossover study versus placebo. Acta Med Scand. 1987; 221:53-60. http://www.ncbi.nlm.nih.gov/pubmed/3551507?dopt=AbstractPlus

157. Aldoori M, Campbell WB, Dieppe PA. Nifedipine in the treatment of Raynaud’s syndrome. Cardiovasc Res. 1986; 20:466-70. http://www.ncbi.nlm.nih.gov/pubmed/3536108?dopt=AbstractPlus

158. Wallace DG, Challenor VF, Francis DA et al. Clinical and rheological effects of nifedipine in Raynaud’s phenomenon. Br J Clin Pharmacol. 1986; 22:449-54. http://www.ncbi.nlm.nih.gov/pubmed/3533127?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1401145&blobtype=pdf

159. Sarkozi J, Bookman AA, Mahon W et al. Nifedipine in the treatment of idiopathic Raynaud’s syndrome. J Rheumatol. 1986; 13:331-6. http://www.ncbi.nlm.nih.gov/pubmed/3723496?dopt=AbstractPlus

160. Corbin DO, Wood DA, Macintyre CC et al. A randomized double-blind cross-over trial of nifedipine in the treatment of primary Raynaud’s phenomenon. Eur Heart J. 1986; 7:165-70. http://www.ncbi.nlm.nih.gov/pubmed/3516704?dopt=AbstractPlus

161. White CJ, Phillips WA, Abrahams LA et al. Objective benefit of nifedipine in the treatment of Raynaud’s phenomenon: double-blind controlled study. Am J Med. 1986; 80:623-5. http://www.ncbi.nlm.nih.gov/pubmed/3515931?dopt=AbstractPlus

162. Pierce EH, DellaValle R, Wielenga J. Raynaud’s disease and nifedipine. Ann Intern Med. 1983; 97:111.

163. Malamet R, Wise RA, Ettinger WH et al. Nifedipine in the treatment of Raynaud’s phenomenon: evidence for inhibition of platelet activation. Am J Med. 1985; 78:602-8. http://www.ncbi.nlm.nih.gov/pubmed/3157318?dopt=AbstractPlus

164. Codella O, Caramaschi P, Olivieri O et al. Controlled comparison of ketanserin and nifedipine in Raynaud’s phenomenon. Angiology. 1989; 40:114-21. http://www.ncbi.nlm.nih.gov/pubmed/2644876?dopt=AbstractPlus

165. Ehrenkranz RA, Ackerman BA, Hulse JD. Nifedipine transfer into human milk. J Pediatr. 1989; 114:478-80. http://www.ncbi.nlm.nih.gov/pubmed/2921695?dopt=AbstractPlus

166. Hansten PD, Horn JR. Drug interactions: clinical significance of drug-drug interactions. 6th ed. Philadelphia: Lea & Febiger; 1989:11.

167. Ahmad S. Nifedipine—phenytoin interaction. J Am Coll Cardiol. 1984; 3:1581.

168. Miles Inc. Nimotop (nimodipine) prescribing information. West Haven, CT; 1989 Mar.

169. Taylor RJ. (Pharmaceutical Division, Miles Inc., West Haven, CT): Personal communication; 1989 Oct 12.

170. Anon. Drugs for hypertensive emergencies. Med Lett Drugs Ther. 1989; 31:32-4. http://www.ncbi.nlm.nih.gov/pubmed/2927362?dopt=AbstractPlus

171. Beer N, Gallegos I, Cohen A et al. Efficacy of sublingual nifedipine in the acute treatment of systemic hypertension. Chest. 1981; 79:571-4. http://www.ncbi.nlm.nih.gov/pubmed/7226935?dopt=AbstractPlus

172. Takekoshi N, Murakami E, Murakami H et al. Treatment of severe hypertension and hypertensive emergency with nifedipine, a calcium antagonistic agent. Jpn Circ J. 1981; 45:852-60. http://www.ncbi.nlm.nih.gov/pubmed/7265456?dopt=AbstractPlus

173. Conen D, Bertel O, Dubach UC. An oral calcium antagonist for treatment of hypertensive emergencies. J Cardiovasc Pharm. 1982; 4:S378-81.

174. Frishman WH, Weinberg P, Peled HB et al. Calcium entry blockers for the treatment of severe hypertension and hypertensive crisis. Am J Med. 1984; 77:35-45. http://www.ncbi.nlm.nih.gov/pubmed/6486126?dopt=AbstractPlus

175. Murphy MB. Treatment of hypertension with calcium antagonists. Int J Clin Pharm Res. 1985; 5:287-91.

176. Erne P, Bolli P, Bertel O et al. Factors influencing the hypotensive effects of calcium antagonists. Hypertension. 1983; 5(Suppl 2):II-97-II-102.

177. Ziegler MG, Lernhardt E, Solt-Buzsaki V et al. Dose response to hydrochlorothiazide in hypertensives receiving a calcium channel blocker. Clin Exp Hypertens. 1988; A10:791-800.

178. Prichard BNC, Tomlinson B. Choice of antihypertensive drug therapy. Am Heart J. 1987; 114:1030-40. http://www.ncbi.nlm.nih.gov/pubmed/2889342?dopt=AbstractPlus

179. Bauer JH. Stepped-care approach to the treatment of hypertension: is it obsolete? (unpublished observations)

180. Anon. 1986 Guidelines for the treatment of mild hypertension: memorandum from the WHO/ISH. Memorandum presented at the 4th mild hypertension conference. Konigstein, Federal Republic of Germany: 1985 Dec 4-7.

181. Epstein M. Targeting antihypertensive therapy to the individual patient. J Clin Hypertens. 1986; 3:62-71S.

182. Morlin C, Baglivo H, Boeijinga JK et al. Comparative trial of lisinopril and nifedipine in mild to severe essential hypertension. J Cardiovasc Pharmacol. 1987; 9(Suppl 3):S48-52. http://www.ncbi.nlm.nih.gov/pubmed/2442552?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=4351551&blobtype=pdf

183. Muller FB, Bolli P, Erne P et al. Use of calcium antagonists as monotherapy in the management of hypertension. Am J Med. 1984; 77:11-5. http://www.ncbi.nlm.nih.gov/pubmed/6385691?dopt=AbstractPlus

184. Klein WW. Treatment of hypertension with calcium channel blockers: European data. Am J Med. 1984; 77:143-6. http://www.ncbi.nlm.nih.gov/pubmed/6385698?dopt=AbstractPlus

185. Gould BA, Hornung RS, Mann S et al. Nifedipine or verapamil as sole treatment of hypertension: an intraarterial study. Hypertension. 1983; 5(Suppl II):II-91-6. http://www.ncbi.nlm.nih.gov/pubmed/6862589?dopt=AbstractPlus

186. Midtbo K, Hals O, Lauve O et al. Studies on verapamil in the treatment of essential hypertension: a review. Br J Clin Pharmacol. 1986; 21(Suppl 2):165-71S. http://www.ncbi.nlm.nih.gov/pubmed/3954932?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1400915&blobtype=pdf

187. Gavras H. The place of angiotensin-converting enzyme inhibition in the treatment of cardiovascular diseases. N Engl J Med. 1988; 319:1541-3. http://www.ncbi.nlm.nih.gov/pubmed/3185679?dopt=AbstractPlus

188. Kostis JB. Angiotensin-converting enzyme inhibitors. Am Heart J. 1988; 116:1591-605. http://www.ncbi.nlm.nih.gov/pubmed/3057846?dopt=AbstractPlus

189. Oates JA, Wood AJJ. Converting enzyme inhibitors in the treatment of hypertension. N Engl J Med. 1988; 319:1517-25. http://www.ncbi.nlm.nih.gov/pubmed/3054561?dopt=AbstractPlus

190. Schuna AA. 1988 Report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure: a commentary. Clin Pharm. 1988; 7:837-41. http://www.ncbi.nlm.nih.gov/pubmed/2904314?dopt=AbstractPlus

191. Murphy MB, Bulpitt CJ, Dollery CT. Role of nifedipine in the treatment of resistant hypertension: comparison with hydralazine in hospital outpatients. Am J Med. 1984; 77:16-21. http://www.ncbi.nlm.nih.gov/pubmed/6486124?dopt=AbstractPlus

192. Sorkin EM, Clissold SP, Brogden RN. Nifedipine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders. Drugs. 1985; 30:182-274. http://www.ncbi.nlm.nih.gov/pubmed/2412780?dopt=AbstractPlus

193. Duffy J, Macdonald G. The antihypertensive efficacy of nifedipine alone and in combination in general practice. Curr Med Res Opin. 1987; 10:566-72. http://www.ncbi.nlm.nih.gov/pubmed/3677791?dopt=AbstractPlus

194. Schulte KL, Meyer-Sabellek WA, Haertenberger A et al. Antihypertensive and metabolic effects of diltiazem and nifedipine. Hypertension. 1986; 8:859-65. http://www.ncbi.nlm.nih.gov/pubmed/3759224?dopt=AbstractPlus

195. Pacheco JP, Fan F, Wright RA et al. Monotherapy of mild hypertension with nifedipine. Am J Med. 1986; 81(Suppl 6A):20-4. http://www.ncbi.nlm.nih.gov/pubmed/3541596?dopt=AbstractPlus

196. Fadayomi MO, Akinroye KK, Ajao RO et al. Monotherapy with nifedipine for essential hypertension in adult blacks. J Cardiovasc Pharmacol. 1986; 8:466-9. http://www.ncbi.nlm.nih.gov/pubmed/2425159?dopt=AbstractPlus

197. Gill JS, Zezulka AV, Beevers M et al. An audit of nifedipine in a hypertension clinic. J Clin Hosp Pharm. 1986; 11:107-16. http://www.ncbi.nlm.nih.gov/pubmed/3711359?dopt=AbstractPlus

198. Frishman WH, Charlap S, Kimmel B et al. Calcium-channel blockers for combined angina pectoris and systemic hypertension. Am J Cardiol. 1986; 57:22-9D.

199. Yagil Y, Kobrin I, Stessman J et al. Acute oral management of hypertension: blood pressure response to prazosin and nifedipine. Isr J Med Sci. 1983; 19:277-9. http://www.ncbi.nlm.nih.gov/pubmed/6853125?dopt=AbstractPlus

200. Donnelly R, Elliott HL, Meredith PA et al. Nifedipine: individual responses and concentration-effect relationships. Hypertension. 1988; 12:443-9. http://www.ncbi.nlm.nih.gov/pubmed/3169952?dopt=AbstractPlus

201. Ekelund LG. Nifedipine in combination therapy for chronic hypertension: a review. Am J Med. 1985; 79(Suppl 4A):41-3. http://www.ncbi.nlm.nih.gov/pubmed/2864857?dopt=AbstractPlus

202. Gavras I, Gavras H. Nifedipine in the treatment of essential hypertension. J Clin Pharmacol. 1985; 25:429-32. http://www.ncbi.nlm.nih.gov/pubmed/3902911?dopt=AbstractPlus

203. Buhler FR, Hulthen UL, Kiowski W et al. The place of the calcium antagonist verapamil in antihypertensive therapy. J Cardiovasc Pharmacol. 1982; (Suppl 3):350-7.

204. Bursztyn M, Grossman E, Rosenthal T. Nifedipine in antihypertensive therapy. Arch Intern Med. 1985; 145:953-4. http://www.ncbi.nlm.nih.gov/pubmed/3994476?dopt=AbstractPlus

205. Evans MG Jr, Olanoff LS, Hurwitz G et al. Use of nifedipine as an adjunct to current antihypertensive therapy. Arch Intern Med. 1984; 144:985-7. http://www.ncbi.nlm.nih.gov/pubmed/6143543?dopt=AbstractPlus

206. Ohman KP, Weiner L, von Schenck H et al. Antihypertensive and metabolic effects of nifedipine and labetalol alone and in combination in primary hypertension. Eur J Clin Pharmacol. 1985; 29:149-54. http://www.ncbi.nlm.nih.gov/pubmed/3908121?dopt=AbstractPlus

207. Robinson BF. Calcium-entry blocking agents in the treatment of systemic hypertension. Am J Cardiol. 1985; 55:102-6B.

208. Murakami E, Takekoshi N, Matsui S et al. Nifedipine in hypertension and heart failure. Clin Ther. 1984; 6:205-36. http://www.ncbi.nlm.nih.gov/pubmed/6705014?dopt=AbstractPlus

209. Mimran A, Ribstein J. Effect of chronic nifedipine in patients inadequately controlled by a converting enzyme inhibitor and a diuretic. J Cardiovasc Pharmacol. 1985; 7(Suppl 1):S92-5. http://www.ncbi.nlm.nih.gov/pubmed/2580184?dopt=AbstractPlus

210. Murphy MB, Scriven AJ, Dollery CT. Efficacy of nifedipine as a step 3 antihypertensive drug. Hypertension. 1983; 5:II-118-21. http://www.ncbi.nlm.nih.gov/pubmed/6345370?dopt=AbstractPlus

211. Yagil Y, Kobrin I, Stessman J et al. Effectiveness of combined nifedipine and propranolol treatment in hypertension. Hypertension. 1983; 5:II-113-7. http://www.ncbi.nlm.nih.gov/pubmed/6862585?dopt=AbstractPlus

212. Bayley S, Dobbs RJ, Robinson BF. Nifedipine in the treatment of hypertension: report of a double-blind controlled trial. Br J Clin Pharmacol. 1982; 14:509-12. http://www.ncbi.nlm.nih.gov/pubmed/6753886?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1427595&blobtype=pdf

213. Zusman R, Christensen D, Federman E et al. Comparison of nifedipine and propranolol used in combination with diuretics for the treatment of hypertension. Am J Med. 1987; 82(Suppl 3B):37-41. http://www.ncbi.nlm.nih.gov/pubmed/3551602?dopt=AbstractPlus

214. Massie BM. Antihypertensive therapy with calcium-channel blockers: comparison with beta blockers. Am J Cardiol. 1985; 56:97-100H.

215. Anon. Drugs for hypertension. Med Lett Drugs Ther. 1987; 29:1-6. http://www.ncbi.nlm.nih.gov/pubmed/3025573?dopt=AbstractPlus

216. Anon. Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension: II. Results of long-term therapy. JAMA. 1982; 248:2004-11. http://www.ncbi.nlm.nih.gov/pubmed/6750167?dopt=AbstractPlus

217. Kaplan NM. Systemic hypertension: therapy. In: Braunwald E, ed. Heart disease: a textbook of cardiovascular medicine. Philadelphia: WB Saunders; 1988:862-83.

218. Holland OB, Fairchild #. Renin classification for diuretic and beta-blocker treatment of black hypertensive patients. J Chron Dis. 1982; 35:179-82. http://www.ncbi.nlm.nih.gov/pubmed/6120945?dopt=AbstractPlus

219. Cubeddu LX, Aranda J, Singh B et al. A comparison of verapamil and propranolol for the initial treatment of hypertension: racial differences in response. JAMA. 1986; 256:2214-21. http://www.ncbi.nlm.nih.gov/pubmed/3531560?dopt=AbstractPlus

220. Bühler FR. Age and cardiovascular response adaptation: determinants of an antihypertensive treatment concept primarily based on beta-blockers and calcium entry blockers. Hypertension. 1983; 5(Suppl III):II-94-100.

221. Piepho RW, Sowers JR. Antihypertensive therapy in the geriatric patient: I. A review of the role of calcium channel blockers. J Clin Pharmacol. 1989; 29:193-200. http://www.ncbi.nlm.nih.gov/pubmed/2656772?dopt=AbstractPlus

222. Kaplan NM. Initial treatment of adult patients with essential hypertension. Part 2: alternating monotherapy is the preferred treatment. Pharmacother. 1985; 5:195-200.

223. Hughes GS Jr, Cowart TD Jr, Conradi EC. Efficacy of verapamil-hydrochlorothiazide-spironoalactone therapy in hypertensive black patients. Clin Pharm. 1987; 6:322-6. http://www.ncbi.nlm.nih.gov/pubmed/3665385?dopt=AbstractPlus

224. Materson BJ, Preston RA. Newer principles of patient profiling for antihypertensive therapy. Circulation. 1989; 90(Suppl IV):IV-128-35.

225. Kiowski W, Bolli P, Erne P et al. Mechanisms of action and clinical use of calcium antagonists in hypertension. Circulation. 1989; 90(Suppl IV):IV-136-44.

226. Frishman WH, Skolnick AE, Strom JA. Effects of calcium entry blockade on hypertension-induced left ventricular hypertrophy. Circulation. 1989; 80(Suppl IV):IV-151-61. http://www.ncbi.nlm.nih.gov/pubmed/2532080?dopt=AbstractPlus

227. Emeriau JP. Guidelines for testing hypertension in the elderly. Drugs. 1989; 38:612-20. http://www.ncbi.nlm.nih.gov/pubmed/2684595?dopt=AbstractPlus

228. Bühler FR, Bolli P, Erne P et al. Position of calcium antagonists in antihypertensive therapy. J Cardiovasc Pharmacol. 1985; 7(Suppl 4):S21-7.

229. Bühler FR, Bolli P, Kiowski W et al. Renin profiling to select antihypertensive baseline drugs. Renin inhibitors for high-renin and calcium entry blockers for low-renin patients. Am J Med. 1984; 77(2A):36-42. http://www.ncbi.nlm.nih.gov/pubmed/6148011?dopt=AbstractPlus

230. Poulter N, Thompson AV, Sever PS. A double-blind, placebo-controlled, crossover trial to investigate the additive hypotensive effect of a diuretic (merfruside) to that produced by nifedipine. J Cardiovasc Pharmacol. 1987; 10(Suppl 10):PS53-6.

231. Ferrara LA, Pasanisi F, Marotta T et al. Calcium antagonists and thiazide diuretics in the treatment of hypertension. J Cardiovasc Pharmacol. 1987; 10(Suppl 10):S136-7. http://www.ncbi.nlm.nih.gov/pubmed/2455115?dopt=AbstractPlus

232. Hallin L, Andren L, Hansson L. Controlled trial of nifedipine and bendroflumethiazide in hypertension. J Cardiovasc Pharmacol. 1983; 5:1083-5. http://www.ncbi.nlm.nih.gov/pubmed/6196558?dopt=AbstractPlus

233. Zezulka AV, Gill JS, Beevers DG. The effects of bendroflumethiazide added to nifedipine in patients with hypertension. J Clin Pharmacol. 1987; 27:41-5. http://www.ncbi.nlm.nih.gov/pubmed/3316303?dopt=AbstractPlus

234. Corcoran JS, Perkins JE, Hoffbrand BI et al. Treating hypertension in non-insulin-dependent diabetes: a comparison of atenolol, nifedipine, and captopril combined with bendrofluazide. Diabetic Med. 1987; 4:164-8. http://www.ncbi.nlm.nih.gov/pubmed/2952436?dopt=AbstractPlus

235. Lamaison D, Abrieu V, Fialip J et al. [Acute intestinal occlusion and calcium antagonists.] (French; with English abstract.) Therapie. 1989; 44:201-2.

236. Qureshi S, Laganiere S, McGilveray IJ et al. Nifedipine-alcohol interaction. JAMA. 1990; 264:1660-1. http://www.ncbi.nlm.nih.gov/pubmed/2398604?dopt=AbstractPlus

238. Weber MA, Laragh JH. Hypertension: steps forward and steps backward: the Joint National Committee fifth report. Arch Intern Med. 1993; 153:149-52. http://www.ncbi.nlm.nih.gov/pubmed/8422205?dopt=AbstractPlus

239. Alderman MH. Which antihypertensive drugs first—and why! JAMA. 1992; 267:2786-7. Editorial.

240. Glasser SP, Clark PI, Lipicky RJ et al. Exposing patients with chronic, stable, exertional angina to placebo periods in drug trials. JAMA. 1991; 265:1550-4. http://www.ncbi.nlm.nih.gov/pubmed/1671885?dopt=AbstractPlus

241. National Heart, Lung, and Blood Institute. NHLBI panel reviews safety of calcium channel blockers. Rockville, MD; 1995 Aug 31. Press release.

242. National Heart, Lung, and Blood Institute. New analysis regarding the safety of calcium-channel blockers: a statement for health professionals from the National Heart, Lung, and Blood Institute. Rockville, MD; 1995 Sep 1.

243. Anon. NHLBI panel stands by JNC V in response to Circulation CCB article; AIM report supports use of beta blockers for prevention of sudden cardiac death. F-D-C Rep. 1995; 57(Sep 4):3-4.

244. American Heart Association. Public advisory statement on calcium channel blocker drugs. Dallas, TX; 1995 Aug 28.

245. Psaty BM, Heckbert SR, Koepsell TD et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA. 1995; 274:620-5. http://www.ncbi.nlm.nih.gov/pubmed/7637142?dopt=AbstractPlus

246. Psaty BM, Heckbert SR, Koepsell TD et al. The risk of incident myocardial infarction associated with anti-hypertensive drug therapies. Circulation. 1995; 91:925.

247. Buring JE, Glynn RJ, Hennekens CH. Calcium channel blockers and myocardial infarction: a hypothesis formulated but not yet tested. JAMA. 1995; 274:654-5. http://www.ncbi.nlm.nih.gov/pubmed/7637148?dopt=AbstractPlus

248. Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation. 1995; 92:1326-31. http://www.ncbi.nlm.nih.gov/pubmed/7648682?dopt=AbstractPlus

249. Opie LH, Messerli FH. Nifedipine and mortality: grave defects in the dossier. Circulation. 1995; 92:1068-73. http://www.ncbi.nlm.nih.gov/pubmed/7648646?dopt=AbstractPlus

250. Kloner RA. Nifedipine in ischemic heart disease. Circulation. 1995; 92:1074-8. http://www.ncbi.nlm.nih.gov/pubmed/7648647?dopt=AbstractPlus

251. Yusuf S. Calcium antagonists in coronary artery disease and hypertension: time for reevaluation? Circulation. 1995; 92:1079-82. Editorial.

252. Lenfant C. The calcium channel blocker scare: lessons for the future. Circulation. 1995; 91:2855-6. http://www.ncbi.nlm.nih.gov/pubmed/7796490?dopt=AbstractPlus

253. Habib GB. Are calcium antagonists harmful in hypertensive patients? Distinguishing hype from reality. Chest. 1995; 108:3-5. http://www.ncbi.nlm.nih.gov/pubmed/7606987?dopt=AbstractPlus

254. Horton R. Spinning the risks and benefits of calcium antagonists. Lancet. 1995; 346:586-7. http://www.ncbi.nlm.nih.gov/pubmed/7650997?dopt=AbstractPlus

255. Yusuf S, Held P, Furberg C. Update of effects of calcium antagonists in myocardial infarction or angina in light of the Second Danish Verapamil Infarction Trial (DAVIT- II) and other recent studies. Am J Cardiol. 1991; 67:1295-7. http://www.ncbi.nlm.nih.gov/pubmed/2035457?dopt=AbstractPlus

256. Egstrup K, Andersen PE Jr. Transient myocardial ischemia during nifedipine therapy in stable angina pectoris, and its relation to coronary collateral flow and comparison with metoprolol. Am J Cardiol. 1993; 71:177-83. http://www.ncbi.nlm.nih.gov/pubmed/8421980?dopt=AbstractPlus

257. Wagenknecht LE, Furberg CD, Hammon JW et al. Surgical bleeding: unexpected effect of a calcium antagonist. BMJ. 1995; 310:776-7. http://www.ncbi.nlm.nih.gov/pubmed/7711582?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=2549165&blobtype=pdf

258. Miles Inc. American Heart Association, Dr. Psalty and Miles Inc. release statements qualifying possible risks of calcium channel blockers. West Haven, CT; 1995 Mar 15. Press release.

259. Dear healthcare professional letter regarding calcium-channel blockers and increased risk of heart attack. Chicago:Searle. 1995 Mar 17.

260. McClellan K. Unexpected results from MIDAS in atherosclerosis. Inpharma Wkly. 1994; Apr 9:4.

261. Anon. Groups act to dispel concerns about calcium-channel blockers. Am J Health-Syst Pharm. 1995; 52:1154, 1158. http://www.ncbi.nlm.nih.gov/pubmed/7656105?dopt=AbstractPlus

262. Waters D. Proischemic complications of dihydropyridine calcium channel blockers. Circulation. 1991; 84:2598-600. http://www.ncbi.nlm.nih.gov/pubmed/1959210?dopt=AbstractPlus

263. Messerli FH. Case-control study, meta-analysis, and bouillabaisse: putting the calcium antagonist scare into context. Ann Intern Med. 1995; 123:888-9. http://www.ncbi.nlm.nih.gov/pubmed/7486476?dopt=AbstractPlus

264. Reviewers’ comments (personal observations).

265. Pratt Pharmacueticals. Procardia (nifedipine) capsules prescribing information (dated 1993 Feb). In: Physicians’ desk reference. 49th ed. Montvale, NJ: Medical Economics Company Inc; 1995:1906-7.

266. Held PH, Yusuf S, Furberg CD. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. BMJ. 1989; 299:1187-92. http://www.ncbi.nlm.nih.gov/pubmed/2513047?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1838102&blobtype=pdf

267. Gales MA. Oral antihypertensives for hypertensive urgencies. Ann Pharmacother. 1994; 28:353-8.

268. McDonald AJ, Yealy DM, Jacobson S. Oral labetalol versus oral nifedipine in hypertensive urgencies in the ED. Am J Emerg Med. 1993; 11:460-3. http://www.ncbi.nlm.nih.gov/pubmed/8363681?dopt=AbstractPlus

269. Angeli P, Chiesa M, Caregaro L et al. Comparison of sublingual captopril and nifedipine in immediate treatment of hypertensive emergencies. Arch Intern Med. 1991; 151:67-82. http://www.ncbi.nlm.nih.gov/pubmed/1824675?dopt=AbstractPlus

270. Jaker M, Atkin S, Soto M et al. Oral nifedipine vs oral clonidine in the treatment of urgent hypertension. Arch Intern Med. 1989; 149:260-5. http://www.ncbi.nlm.nih.gov/pubmed/2916871?dopt=AbstractPlus

271. Spah F, Grosser KD. Treatment of hypertensive urgencies and emergencies with nitrendipine, nifedipine, and clonidine: effect on blood pressure and heart rate. J Cardiovasc Pharmacol. 1988; 12(Suppl):S154-6. http://www.ncbi.nlm.nih.gov/pubmed/2468862?dopt=AbstractPlus

272. Komsuoglu V, Sengun B, Bayram A et al. Treatment of hypertensive urgencies and emergencies with oral nifedipine, nicardipine and captopril. Angiology. 1991; 12:147-154.

273. Savi L, Montebelli MR, D’Alonzo S et al. Sublingual nicardipine versus nifedipine to treat hypertensive urgencies. Int J Clin Pharmacol Ther Toxicol. 1992; 30:41-45. http://www.ncbi.nlm.nih.gov/pubmed/1551744?dopt=AbstractPlus

274. Komsuoglu SS, Komsuoglu B, Ozmenoglu M et al. Oral nifedipine in treatment of hypertensive crises in patients with hypertensive encephalopathy. Int J Cardiol. 1992; 34:277-82. http://www.ncbi.nlm.nih.gov/pubmed/1563853?dopt=AbstractPlus

275. Schillenger D. Nifedipine in hypertensive emergencies: a prospective study. J Emerg Med. 1987; 5:463-73. http://www.ncbi.nlm.nih.gov/pubmed/3323299?dopt=AbstractPlus

276. Calhoun DA, Oparil S. Treatment of hypertensive crisis. N Engl J Med. 1990; 323:1177-83. http://www.ncbi.nlm.nih.gov/pubmed/2215596?dopt=AbstractPlus

277. Gonzalez-Carmona VM, Ibarra-Perez C, Jerjes-Sanchez C. Single-dose sublingual nifedipine as the only treatment in hypertensive urgencies and emergencies. Angiology. 1991; 42:908-13. http://www.ncbi.nlm.nih.gov/pubmed/1952278?dopt=AbstractPlus

278. Pascale C, Zampaglione B, Marchisio M. Management of hypertensive crisis: nifedipine in comparison with captopril, clonidine, and furosemide. Curr Ther Res. 1992; 51:9-18.

279. Maharaj B, van der Byl K. A comparison of the acute hypotensive effects of two different doses of nifedipine. Am Heart J. 1992; 124:720-5. http://www.ncbi.nlm.nih.gov/pubmed/1514500?dopt=AbstractPlus

280. Visser W, Wallenburg HC. A comparison between the haemodynamic effects of oral nifedipine and intravenous dihydralazine in patients with severe pre-eclampsia. J Hypertens. 195; 13:791-5.

281. Rohr G, Reimnitz P, Blanke P. Treatment of hypertensive emergency. Intensive Care Med. 1994; 20:268-71. http://www.ncbi.nlm.nih.gov/pubmed/8046120?dopt=AbstractPlus

282. Wu SG, Lin SL, Shiao WY et al. Comparison of sublingual captopril, nifedipine and prazosin in hypertensive emergencies during hemodialysis. Nephron. 1993; 65:284-7. http://www.ncbi.nlm.nih.gov/pubmed/8247194?dopt=AbstractPlus

283. Grossman E, Messerli FH, Grodzicki T et al. Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies. JAMA. 1996; 276:1328-31. http://www.ncbi.nlm.nih.gov/pubmed/8861992?dopt=AbstractPlus

284. Pfizer Inc. Procardia (nifedipine) capsules prescribing information. New York, NY; 2000 Sep.

285. Gifford RW. Management of hypertensive crises. JAMA. 1991; 266:829-35. http://www.ncbi.nlm.nih.gov/pubmed/1865522?dopt=AbstractPlus

286. Shettigar UR, Loungani R. Adverse effects of sublingual nifedipine in acute myocardial infarction. Crit Care Med. 1989; 17:196-7. http://www.ncbi.nlm.nih.gov/pubmed/2914455?dopt=AbstractPlus

287. Aromatorio GJ, Uretsky BF, Reddy PS. Hypotension and sinus arrest with nifedipine in pulmonary hypertension. Chest. 1985; 87:265-7. http://www.ncbi.nlm.nih.gov/pubmed/3967536?dopt=AbstractPlus

288. Rehman F, Mansoor GA, White W. “Inappropriate” physician habits in prescribing oral nifedipine capsules in hospitalized patients. Am J Hyperten. 1996; 9:1035-9.

289. Opie LH. Sublingual nifedipine. Lancet. 1991; 338:1203. http://www.ncbi.nlm.nih.gov/pubmed/1682608?dopt=AbstractPlus

290. American College of Obstetricians and Gynecologists (ACOG) Committee on Technical Bulletins. Preterm labor. Washington, DC; American College of Obstetricians and Gynecologists: 1995 Jun. Technical Bulletin No. 206.

291. Kupferminc M, Lessing JB, Yaron Y et al. Nifedipine versus ritodrine for suppression of preterm labour. Br J Obstet Gynaecol. 1993; 100:1090-4. http://www.ncbi.nlm.nih.gov/pubmed/8297841?dopt=AbstractPlus

292. Read MD, Wellby DE. The use of a calcium antagonist (nifedipine) to suppress preterm labour. Br J Obstet Gynaecol. 1986; 93:933-7. http://www.ncbi.nlm.nih.gov/pubmed/3533134?dopt=AbstractPlus

293. Ferguson JE II, Dyson DC, Schutz T et al. A comparison of tocolysis with nifedipine or ritodrine: analysis of efficacy and maternal, fetal, and neonatal outcome. Am J Obstet Gynecol. 1990; 163:105-11. http://www.ncbi.nlm.nih.gov/pubmed/2197860?dopt=AbstractPlus

294. Glock JL, Morales WJ. Efficacy and safety of nifedipine versus magnesium sulfate in the management of preterm labor: a randomized study. Am J Obstet Gynecol. 1993; 169:960-4. http://www.ncbi.nlm.nih.gov/pubmed/8238157?dopt=AbstractPlus

295. Messerli FH, Kowey P, Grodzicki T. Sublingual nifedipine for hypertensive emergencies. Lancet. 1991; 338:881. http://www.ncbi.nlm.nih.gov/pubmed/1681227?dopt=AbstractPlus

296. Landry GJ, Edwards JM, Porter JM. Current management of Raynaud’s syndrome. Adv Surg. 1996; 30:333-47. http://www.ncbi.nlm.nih.gov/pubmed/8960343?dopt=AbstractPlus

297. Belch JJF, Ho M. Pharmacotherapy of Raynaud’s phenomenon. Drugs. 1996; 52:682-95. http://www.ncbi.nlm.nih.gov/pubmed/9118818?dopt=AbstractPlus

298. Opie LH. Calcium channel antagonists should be among the first-line drugs in the management of cardiovascular disease. Cardiovasc Drugs Ther. 1996; 10:455-61. http://www.ncbi.nlm.nih.gov/pubmed/8924059?dopt=AbstractPlus

299. Nobile-Razio E, Sterzi R. Cerebral ischemia after nifedipine treatment. BMJ. 1981; 283:948. http://www.ncbi.nlm.nih.gov/pubmed/6793184?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1507221&blobtype=pdf

300. Schwartz M, Naschitz JE, Yeshurun D et al. Oral nifedipine in the treatment of hypertensive urgency: cerebrovascular accident following a single dose. Arch Intern Med. 1990; 150:686-7. http://www.ncbi.nlm.nih.gov/pubmed/2310288?dopt=AbstractPlus

301. Zangerle KF, Wolford R. Syncope and conduction disturbances following sublingual nifedipine for hypertension. Ann Emerg Med. 1985; 14:1005-6. http://www.ncbi.nlm.nih.gov/pubmed/4037465?dopt=AbstractPlus

302. Leavitt AD, Zweifler AJ, Meriden T et al. Nifedipine, hypotension, and myocardial injury. Ann Intern Med. 1988; 108:305-6. http://www.ncbi.nlm.nih.gov/pubmed/3341662?dopt=AbstractPlus

303. O’Mailia JJ, Sander GE, Giles TD. Nifedipine-associatetd myocardial ischemia or infarctionin the treatment of hypertensive urgencies. Ann Intern Med. 1987; 107:185-6. http://www.ncbi.nlm.nih.gov/pubmed/3605898?dopt=AbstractPlus

304. Impey L. Severe hypotension and fetal distress following sublingual administration of nifedipine to a patients with severe pregnancy induced hypertension at 33 weeks. Br J Obstet Gynaecol. 1993; 100:959-61. http://www.ncbi.nlm.nih.gov/pubmed/8217985?dopt=AbstractPlus

305. Finch MB, Copeland S, Passmore AP et al. A double-blind cross-over study of nifedipine retard in patients withRaynaud’s phenomenon. Clin Rheumatol. 1988; 7:359-65. http://www.ncbi.nlm.nih.gov/pubmed/3067954?dopt=AbstractPlus

306. Waller DG, Challenor VF, Francis DA et al. Clinical and rheumatological effects of nifedipine in Raynaud’s phenomenon. Br J Clin Pharmacol. 1986; 22:449-54. http://www.ncbi.nlm.nih.gov/pubmed/3533127?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1401145&blobtype=pdf

307. Bayer Corporation. Adalat (nifedipine) capsules prescribing information (dated 1996 Mar). In: Physicians’ desk reference. 51st ed. Montvale, NJ: Medical Economics Company Inc; 1997:580-2.

308. Woodmansky P, Chaner KS. Nifedipine and hypotension. Lancet. 1991; 338:763-4.

309. The Guidelines Subcommitee of the WHO/ISH Mild Hypertension liason Committee. 1993 guidelines for the managment of mild hypertension: memorandum from a World Health Organization/International Society of Hypertension meeting. Hypertension. 1993; 22:392-403. http://www.ncbi.nlm.nih.gov/pubmed/8349333?dopt=AbstractPlus

310. Boden WE, Korr KS, Bough EW. Nifedipine-induced hypotension and myocardial ischemia in refractory angina pectoris. JAMA. 1985; 253:1131-5. http://www.ncbi.nlm.nih.gov/pubmed/2857206?dopt=AbstractPlus

311. Anon. Grapefruit juice interactions with drugs. Med Lett Drugs Ther. 1995; 37:73-4. http://www.ncbi.nlm.nih.gov/pubmed/7630329?dopt=AbstractPlus

312. Kupferschmidt HHT, Ha HR, Ziegler WH et al. Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther. 1995; 58:20-8. http://www.ncbi.nlm.nih.gov/pubmed/7628179?dopt=AbstractPlus

313. Hukkinen SK, Varhe A, Olkkola KT et al. Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice. Clin Pharmacol Ther. 1995; 58:127-31. http://www.ncbi.nlm.nih.gov/pubmed/7648762?dopt=AbstractPlus

314. Bailey DG, Arnold JMO, Spence JD. Grapefruit juice and drugs: how significant is the interaction? Clin Pharmcokinet. 1994; 26:91-8.

315. Benton RE, Honig PK, Zamani K et al. Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram. Clin Pharmacol Ther. 1996; 59:383-8. http://www.ncbi.nlm.nih.gov/pubmed/8612381?dopt=AbstractPlus

316. Ducharme MP, Warbasse LH, Edwards DJ. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther. 1995; 57:485-91. http://www.ncbi.nlm.nih.gov/pubmed/7768070?dopt=AbstractPlus

317. Cyclosporine/food (grapefruit juice). In: Tatro DS, Olin BR, Hebel SK eds. Drug interaction facts. St. Louis: JB Lippincott Co; 1996(July):233b.

318. Midazolam (Versed) interactions: grapefruit juice. In: Hansten PD, Horn JR. Drug interactions and updates. Vancouver, WA: Applied Therapeutics, Inc; 1996:932.

319. Proppe DG, Hoch OD, McLean AJ et al. Influence of chronic ingestion of grapefruit juice on steady-state blood concentrations of cyclosporine A in renal transplant patients with stable graft function. Br J Clin Pharmacol. 1995; 39:337-8. http://www.ncbi.nlm.nih.gov/pubmed/7619679?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1365014&blobtype=pdf

320. Ameer B, Weintraub RA, Johnson JV et al. Flavanone absorption after naringin, hesperidin, and citrus administration. Clin Pharmacol Ther. 1996; 60:34-40. http://www.ncbi.nlm.nih.gov/pubmed/8689809?dopt=AbstractPlus

321. Edwards DJ, BellevueFH, Woster PM. Identification of 6′,7′-dihydroxybergamottin, a cytochrome P450 inhibitor in grapefruit juice. Drug Metabol Dispos. (in press)

322. Edwards DJ, Bernier SM. Naringin and naringenin are not the primary CYP3A inhibitors in grapefruit juice. Life Sci. 1996; 59:1025-30. http://www.ncbi.nlm.nih.gov/pubmed/8809221?dopt=AbstractPlus

323. Lundahl J, Regardh CG, Edgar B et al. Relationship between time of intake of grapefruit juice and its effect on pharmacokinetics and pharmacodynamics of felodipine in healthy subjects. Eur J Clin Pharmacol. 1995; 49:61-7. http://www.ncbi.nlm.nih.gov/pubmed/8751023?dopt=AbstractPlus

324. Bailey DG, Spence JD, Munoz C et al. Interaction of citrus juices with felodipine and nifedipine. Lancet. 1991; 337:268-9. http://www.ncbi.nlm.nih.gov/pubmed/1671113?dopt=AbstractPlus

325. Yee GC, Stanley DL, Pessa LJ et al. Effect of grapefruit juice on blood cyclosporin concentration. Lancet. 1995; 345:955-6. http://www.ncbi.nlm.nih.gov/pubmed/7715295?dopt=AbstractPlus

326. Hollander AAMJ, van Rooij J, Lentjes EGWM et al. The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients. Clin Pharmacol Ther. 1995; 57:318-24. http://www.ncbi.nlm.nih.gov/pubmed/7697949?dopt=AbstractPlus

327. Merkel U, Sigusch H, Hoffmann A. Grapefruit juice inhibits 7-hydroxylation of coumarin in healthy volunteers. Eur J Clin Pharmacol. 1994; 46:175-7. http://www.ncbi.nlm.nih.gov/pubmed/8039540?dopt=AbstractPlus

328. Soons PA, Vogels BAPM, Roosemalen MCM et al. Grapefruit juice and cimetidine inhibit stereoselective metabolism of nitrendipine in humans. Clin Pharmacol Ther. 1991; 50:394-403. http://www.ncbi.nlm.nih.gov/pubmed/1914375?dopt=AbstractPlus

329. Fuhr U, Klittich K, Staib AH. Inhibitory effect of grapefruit juice and its bitter principal, naringenin, on CYP1A2 dependent metabolism of caffeine in man. Br J Clin Pharmacol. 1993; 35:431-6. http://www.ncbi.nlm.nih.gov/pubmed/8485024?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1381556&blobtype=pdf

330. Campana C, Regazzi MB, Buggia I et al. Clinically significant drug interactions with cyclosporin: an update. Clin Pharmacokinet. 1996; 30:141-179. http://www.ncbi.nlm.nih.gov/pubmed/8906896?dopt=AbstractPlus

331. Sunahara JF, Gore-Harper ML, Nash KS. Possible erythromelalgia-like syndrome associated with nifedipine in a patient with Raynaud’s phenomenon. Ann Pharmacother. 1996; 30:484-6. http://www.ncbi.nlm.nih.gov/pubmed/8740329?dopt=AbstractPlus

332. Eli Lilly Co. Quinidine gluconate injection prescribing information. Indianapolis, IN; 1995 Oct.

333. Van Lith RM, Appleby DH. Quinidine-nifedipine interaction. Drug Intell Clin Pharm. 1985; 19:829-31. http://www.ncbi.nlm.nih.gov/pubmed/4064916?dopt=AbstractPlus

334. Nifedipine/quinidine. In: Tatro DS, Olin BR, eds. Drug interaction facts. St. Louis: JB Lippincott Co; 1990:606.

335. Green JA, Clementi WA, Porter C et al. Nifedipine/quinidine interaction. Clin Pharm. 1983; 2:461-5. http://www.ncbi.nlm.nih.gov/pubmed/6627876?dopt=AbstractPlus

336. Munger MA, Jarvis RC, Nair R et al. Elucidation of the nifedipine/quinidine interaction. Clin Pharmacol Ther. 1989; 45:411-6. http://www.ncbi.nlm.nih.gov/pubmed/2702799?dopt=AbstractPlus

337. Farringer JA, Green JA, O’Rourke RA et al. Nifedipine-induced alterations in serum quinidine concentrations. Am Heart J. 1984; 108:1570-2. http://www.ncbi.nlm.nih.gov/pubmed/6507260?dopt=AbstractPlus

338. Messerli FH, Grossman E, Grodzicki T et al. Nifedipine for hypertensive emergencies. JAMA. 1997; 277:791. http://www.ncbi.nlm.nih.gov/pubmed/9052707?dopt=AbstractPlus

339. Winker MA. Nifedipine for hypertensive emergencies. JAMA. 1997; 277:791-2. http://www.ncbi.nlm.nih.gov/pubmed/9052707?dopt=AbstractPlus

340. Pfizer, New York, NY: Personal communication.

341. Bayer, West Haven, CT: Personal communication.

342. Bayer. Adalat CC (nifedipine) extended-release tablets prescribing information. West Haven, CT; 2004 Oct.

343. Pfizer Inc. Procardia XL (nifedipine) extended-release tablets prescribing information (dated 1996 Mar). In: Physicians’ desk reference. 51st ed. Montvale, NJ: Medical Economics Company Inc; 1997:2026-8.

344. Anon. Safety of calcium-channel blockers. Med Lett Drugs Ther. 1997; 39:13-4. http://www.ncbi.nlm.nih.gov/pubmed/9040648?dopt=AbstractPlus

345. Psaty BM, Smith NL, Siscovich DS et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. JAMA. 1997; 277:739-45. http://www.ncbi.nlm.nih.gov/pubmed/9042847?dopt=AbstractPlus

346. Manolio TA, Cutler JA, Furberg CD et al. Trends in pharmacologic management of hypertension in the United States. Arch Intern Med. 1995; 155:829-37. http://www.ncbi.nlm.nih.gov/pubmed/7717791?dopt=AbstractPlus

347. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med. 1996; 125:605-13.

348. Epstein M. Calcium antagonists should continue to be used for first-line treatment of hypertension. Arch Intern Med. 1995; 155:2150-6. http://www.ncbi.nlm.nih.gov/pubmed/7487236?dopt=AbstractPlus

349. Abdelwahab W, Frishman W, Landau A. Management of hypertensive urgencies and emergencies. J Clin Pharmacol. 1995; 35:747-62. http://www.ncbi.nlm.nih.gov/pubmed/8522630?dopt=AbstractPlus

351. Kaplan NM. Choice of initial therapy for hypertension. JAMA. 1996; 275:1577-80. http://www.ncbi.nlm.nih.gov/pubmed/8622249?dopt=AbstractPlus

352. American College of Cardiology and American Heart Association. ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol. 1996; 28:1328-428. http://www.ncbi.nlm.nih.gov/pubmed/8890834?dopt=AbstractPlus

354. Stason WB, Schmid CH, Niedzwiecki D et al. Safety of nifedipine in patients with hypertension: a meta-analysis. Hypertension. 1997; 30:7-14. http://www.ncbi.nlm.nih.gov/pubmed/9231814?dopt=AbstractPlus

355. Muller JE, Morrison J, Stone PH et al. Nifedipine therapy for patients wtih threatened and acute myocardial infarction: a randomized, double-blind, placebo-controlled comparison. Circulation. 1984; 69:740-7. http://www.ncbi.nlm.nih.gov/pubmed/6365350?dopt=AbstractPlus

356. Sirnes PA, Overskeid K, Pedersen TR et al. Evolution of infarct size during the early use of nifedipine in patients with acute myocardial infarction: the Norwegian Nifedipine Multicenter Trial. Circulation. 1984; 70:638-44. http://www.ncbi.nlm.nih.gov/pubmed/6383655?dopt=AbstractPlus

357. Wilcox RG, Hampton JR, Banks DC et al. Trial of early nifedipine in acute myocardial infarction: the TRENT study. BMJ. 1986; 293:1204-8. http://www.ncbi.nlm.nih.gov/pubmed/3096431?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1341981&blobtype=pdf

358. The Israeli Sprint Study Group. Secondary Prevention Reinfarction Israeli Nifedipine Trial (SPRINT): a randomized intervention trial of nifedipine in patients with acute myocardial infarction. Eur Heart J. 1988; 9:354-64. http://www.ncbi.nlm.nih.gov/pubmed/2898363?dopt=AbstractPlus

359. Goldbourt U, Behar S, Reicher-Reiss H et al. Early administration of nifedipine in suspected acute myocardial infarction: the Secondary Prevention Reinfarction Israel Nifedipine Trial 2 Study. Arch Intern Med. 1993; 153:345-53. http://www.ncbi.nlm.nih.gov/pubmed/8285927?dopt=AbstractPlus

360. Whelton PK, Appel LJ, Espeland MA et al. for the TONE Collaborative Research group. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). JAMA. 1998; 279:839-46. http://www.ncbi.nlm.nih.gov/pubmed/9515998?dopt=AbstractPlus

361. Velussi M, Brocco E, Frigato F et al. Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Diabetes. 1996; 45:216-22. http://www.ncbi.nlm.nih.gov/pubmed/8549868?dopt=AbstractPlus

362. Estacio RO, Jeffers BW, Hiatt WR et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med. 1998; 338:645-52. http://www.ncbi.nlm.nih.gov/pubmed/9486993?dopt=AbstractPlus

363. Pahor M, Psaty BM, Furberg CD. Treatment of hypertensive patients with diabetes. Lancet. 1998; 351:689-90. http://www.ncbi.nlm.nih.gov/pubmed/9504510?dopt=AbstractPlus

364. Tatti P, Pahor M, Byington RP et al. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care. 1998; 21:597-603. http://www.ncbi.nlm.nih.gov/pubmed/9571349?dopt=AbstractPlus

365. Byington RP, Craven TE, Furberg CD et al. Isradipine, raised glycosylated haemoglobin, and risk of cardiovascular events. Lancet. 1997; 350:1075-6. http://www.ncbi.nlm.nih.gov/pubmed/10213554?dopt=AbstractPlus

366. Alderman M, Madhavan S, Cohen H. Calcium antagonists and cardiovascular events in patients with hypertension and diabetes. Lancet. 1998; 351:216-7. http://www.ncbi.nlm.nih.gov/pubmed/9449897?dopt=AbstractPlus

367. Josefson D. Infarction risk found with calcium channel blocker. BMJ. 1998; 316:797.

368. Cutler JA. Calcium-channel blockers for hypertension—uncertainty continues. N Engl J Med. 1998; 338:679-81. http://www.ncbi.nlm.nih.gov/pubmed/9486999?dopt=AbstractPlus

369. Bayer, West Haven, CT: Personal communication.

370. Bakris GL, Copley JB, Vicknair N et al. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int. 1996; 50:1641-50. http://www.ncbi.nlm.nih.gov/pubmed/8914031?dopt=AbstractPlus

371. Ameer B, Weintraub RA. Drug interactions with grapefruit juice. Clin Phramacokinet. 1997; 33:103-21.

372. Roller L. Drugs and grapefruit juice. Clin Pharmacol Ther. 1998; 63:87. http://www.ncbi.nlm.nih.gov/pubmed/9465845?dopt=AbstractPlus

373. Spence JD. Drugs and grapefruit juice. Clin Pharmacol Ther. 1998; 63:87-8. http://www.ncbi.nlm.nih.gov/pubmed/9465845?dopt=AbstractPlus

374. Izzo JL, Levy D, Black HR. Importance of systolic blood pressure in older Americans. Hypertension. 2000; 35:1021-4. http://www.ncbi.nlm.nih.gov/pubmed/10818056?dopt=AbstractPlus

375. Frohlich ED. Recognition of systolic hypertension for hypertension. Hypertension. 2000; 35:1019-20. http://www.ncbi.nlm.nih.gov/pubmed/10818055?dopt=AbstractPlus

376. Bakris GL, Williams M, Dworkin L et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis. 2000; 36:646-61. http://www.ncbi.nlm.nih.gov/pubmed/10977801?dopt=AbstractPlus

377. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998; 351:1755-62. http://www.ncbi.nlm.nih.gov/pubmed/9635947?dopt=AbstractPlus

378. Aventis Pharmaceuticals. Synercid (quinupristin/dalfopristin) for injection prescribing information. Collegeville, PA; 1999 July.

381. Appel LJ. The verdict from ALLHAT—thiazide diuretics are the preferred initial therapy for hypertension. JAMA. 2002; 288:3039-60. http://www.ncbi.nlm.nih.gov/pubmed/12479770?dopt=AbstractPlus

382. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-riskhypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288:2981-97. http://www.ncbi.nlm.nih.gov/pubmed/12479763?dopt=AbstractPlus

385. Gibbons RJ, Abrams J, Chatterjee K et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol. 2003; 41:159-68. http://www.ncbi.nlm.nih.gov/pubmed/12570960?dopt=AbstractPlus

387. Gersh BJ, Braunwald E, Bonow RO. Chronic coronary artery disease. In: Braunwald E, ed. Heart disease: a textbook of cardiovascular medicine. 6th ed. Philadelphia: WB Saunders Company; 2001:1297.

388. ACOG task force on hypertension in pregnancy: hypertension in pregnancy. Washington, DC: American College of Obstetricians and Gynecologists; 2013.

389. American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins. Management of preterm labor. Washington, DC; American College of Obstetricians and Gynecologists: 2003 May. Practice Bulletin No. 43.

390. King JF, Flenady NJ, Papatsonis DNM et al. Calcium channel blockers for inhibiting preterm labor. Cochrane Database Syst Rev. 2003;(1):CD002255.

391. Ryan TJ, Antman EM, Brooks NH et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. From ACC web site. http://www.cardiosource.org/Science-And-Quality/Practice-Guidelines-and-Quality-Standards.aspx

396. Nifedipine (Procardia) interactions: quinidine. In: Hansten PD, Horn JR. Hansten and Horn’s drug interactions analysis and management. St. Louis, MO: Facts and Comparisons; 1997:408.

397. Mutual. Quinidine gluconate extended-release tablets prescribing information. Philadelphia, PA; 2004 Jan.

398. Diltiazem (Cardizem) interactions: nifedipine (Procardia). In: Hansten PD, Horn JR. Hansten and Horn’s drug interactions analysis and management. St. Louis, MO: Facts and Comparisons; 1997:243.

399. Forest Pharmaceuticals, Inc. Tiazac (diltiazem hydrochloride) extended release capsules prescribing information. St. Louis, MO; 2003 Jul.

400. Doxazosin (Cardura) interactions: nifedipine (Procardia). In: Hansten PD, Horn JR. Hansten and Horn’s drug interactions analysis and management. St. Louis, MO: Facts and Comparisons; 1997:253.

401. Aventis. Rifadin (rifampin capsules) and Rifadin I.V. (rifampin for injection) prescribing information. Bridgewater, NJ; 2004 Jan.

402. Glaxo Inc. Zantac (ranitidine hydrochloride) tablets, GELdose capsules, EFFERdose tablets and granules, and syrup prescribing information. Research Triangle Park, NC; 1999 Nov 2.

403. Glaxo Inc. Product Monograph on Zantac. Research Triangle Park, NC; 1983 Apr.

404. Henry DA, MacDonald IA, Kitchingman G et al. Cimetidine and ranitidine: comparison of effects on hepatic drug metabolism. Br Med J. 1980; 281:775-7. http://www.ncbi.nlm.nih.gov/pubmed/6107157?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1714006&blobtype=pdf

405. Jack D, Richard DA. Cimetidine and ranitidine. Lancet. 1982; 1:914. http://www.ncbi.nlm.nih.gov/pubmed/6122133?dopt=AbstractPlus

406. Rendic S, Alebic-Kolbah T, Kajfez F et al. Interaction of ranitidine with liver microsomes. Xenobiotica. 1982; 12:9-17. http://www.ncbi.nlm.nih.gov/pubmed/6124064?dopt=AbstractPlus

407. Spahn H, Mutschler E, Kirch W et al. Influence of ranitidine on plasma metoprolol concentrations. Br Med J. 1983; 287:838. http://www.ncbi.nlm.nih.gov/pubmed/6311317?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1549104&blobtype=pdf

408. Powell JR, Donn KH. The pharmacokinetic basis for H2-antagonist drug interactions: concepts and implications. J Clin Gastroenterol. 1983; 5(Suppl 1):95-113. http://www.ncbi.nlm.nih.gov/pubmed/6140286?dopt=AbstractPlus

409. Aventis Pharmaceuticals Inc. Anzemet (dolasetron mesylate injection) prescribing information. Kansas City, MO; 1999 Feb.

410. Aventis Pharmaceuticals Inc. Anzemet (dolasetron mesylate tablets) prescribing information. Kansas City, MO; 2000 Jun.

411. Balfour JA, Goa KL. Dolasetron: a review of its pharmacology and therapeutic potential in the management of nausea and vomiting induced by chemotherapy, radiotherapy or surgery. Drugs. 1997; 54:273-98. http://www.ncbi.nlm.nih.gov/pubmed/9257083?dopt=AbstractPlus

412. Astellas Pharma US, Inc. Prograf (tacrolimus) capsules and injection prescribing information. Deerfield, IL; 2006 Apr.

413. Wyeth Laboratories. Rapamune (sirolimus) oral solution and tablets prescribing information. Philadelphia, PA; 2003 Apr.

414. Vasquez EM. Sirolimus: a new agent for prevention of renal allograft rejection. Am J Health-Syst Pharm. 2000; 57:437-51. http://www.ncbi.nlm.nih.gov/pubmed/10711524?dopt=AbstractPlus

415. Wright JT, Dunn JK, Cutler JA et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA. 2005; 293:1595-607. http://www.ncbi.nlm.nih.gov/pubmed/15811979?dopt=AbstractPlus

416. Neaton JD, Kuller LH. Diuretics are color blind. JAMA. 2005; 293:1663-6. Editorial. http://www.ncbi.nlm.nih.gov/pubmed/15811986?dopt=AbstractPlus

417. Leenen FHH, Nwachuku CE, Black HR et al. Clinical events in high-risk hypertensive patients randomly assigned to calcium-channel blocker versus angiotensin-converting enzyme inhibitor in the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial. Hypertension. 2006; 48:374-84. http://www.ncbi.nlm.nih.gov/pubmed/16864749?dopt=AbstractPlus

418. Messerli FH, Staessen JA. Amlodipine better than lisinopril: how one randomized clinical trial ended fallacies from observational studies? Hypertension . 2006; 48:359-61. Editorial.

419. Simhan HN, Caritis SN. Prevention of preterm delivery. N Engl J Med. 2007; 357:477-87. http://www.ncbi.nlm.nih.gov/pubmed/17671256?dopt=AbstractPlus

420. Sayres WG. Preterm labor. Am Fam Physician. 2010; 81:477-84. http://www.ncbi.nlm.nih.gov/pubmed/20148502?dopt=AbstractPlus

421. Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 2006; 3:CD004454.

501. James PA, Oparil S, Carter BL et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014; 311:507-20. http://www.ncbi.nlm.nih.gov/pubmed/24352797?dopt=AbstractPlus

502. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013; 31:1281-357. http://www.ncbi.nlm.nih.gov/pubmed/23817082?dopt=AbstractPlus

503. Go AS, Bauman MA, Coleman King SM et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. Hypertension. 2014; 63:878-85. http://www.ncbi.nlm.nih.gov/pubmed/24243703?dopt=AbstractPlus

504. Weber MA, Schiffrin EL, White WB et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich). 2014; 16:14-26. http://www.ncbi.nlm.nih.gov/pubmed/24341872?dopt=AbstractPlus

505. Wright JT, Fine LJ, Lackland DT et al. Evidence supporting a systolic blood pressure goal of less than 150 mm Hg in patients aged 60 years or older: the minority view. Ann Intern Med. 2014; 160:499-503. http://www.ncbi.nlm.nih.gov/pubmed/24424788?dopt=AbstractPlus

506. Mitka M. Groups spar over new hypertension guidelines. JAMA. 2014; 311:663-4. http://www.ncbi.nlm.nih.gov/pubmed/24549531?dopt=AbstractPlus

507. Peterson ED, Gaziano JM, Greenland P. Recommendations for treating hypertension: what are the right goals and purposes?. JAMA. 2014; 311:474-6. http://www.ncbi.nlm.nih.gov/pubmed/24352710?dopt=AbstractPlus

508. Bauchner H, Fontanarosa PB, Golub RM. Updated guidelines for management of high blood pressure: recommendations, review, and responsibility. JAMA. 2014; 311:477-8. http://www.ncbi.nlm.nih.gov/pubmed/24352759?dopt=AbstractPlus

510. Staessen JA, Fagard R, Thijs L et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997; 350:757-64. http://www.ncbi.nlm.nih.gov/pubmed/9297994?dopt=AbstractPlus

511. JATOS Study Group. Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res. 2008; 31:2115-27. http://www.ncbi.nlm.nih.gov/pubmed/19139601?dopt=AbstractPlus

515. Thomas G, Shishehbor M, Brill D et al. New hypertension guidelines: one size fits most?. Cleve Clin J Med. 2014; 81:178-88. http://www.ncbi.nlm.nih.gov/pubmed/24591473?dopt=AbstractPlus

516. Wright JT, Bakris G, Greene T et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002; 288:2421-31. http://www.ncbi.nlm.nih.gov/pubmed/12435255?dopt=AbstractPlus

520. American Diabetes Association. Standards of medical care in diabetes--2014. Diabetes Care. 2014; 37 Suppl 1:S14-80.

522. Patel A, ADVANCE Collaborative Group, MacMahon S et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007; 370:829-40. http://www.ncbi.nlm.nih.gov/pubmed/17765963?dopt=AbstractPlus

523. Fihn SD, Gardin JM, Abrams J et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012; 126:e354-471.

524. WRITING COMMITTEE MEMBERS, Yancy CW, Jessup M et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013; 128:e240-327.

525. Smith SC, Benjamin EJ, Bonow RO et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011; 124:2458-73. http://www.ncbi.nlm.nih.gov/pubmed/22052934?dopt=AbstractPlus

526. Kernan WN, Ovbiagele B, Black HR et al. Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2014; :. http://www.ncbi.nlm.nih.gov/pubmed/24788967?dopt=AbstractPlus

527. O'Gara PT, Kushner FG, Ascheim DD et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013; 127:e362-425. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=3695607&blobtype=pdf

530. Myers MG, Tobe SW. A Canadian perspective on the Eighth Joint National Committee (JNC 8) hypertension guidelines. J Clin Hypertens (Greenwich). 2014; 16:246-8. http://www.ncbi.nlm.nih.gov/pubmed/24641124?dopt=AbstractPlus

535. Taler SJ, Agarwal R, Bakris GL et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD. Am J Kidney Dis. 2013; 62:201-13. http://www.ncbi.nlm.nih.gov/pubmed/23684145?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=3929429&blobtype=pdf

536. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl. 2012: 2: 337-414.

540. Magee LA, Pels A, Helewa M et al., for the Canadian Hypertensive Disorders of Pregnancy (HDP) Working Group. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. Pregnancy Hypertens. 2014; 4:105-45. http://www.ncbi.nlm.nih.gov/pubmed/26104418?dopt=AbstractPlus

541. Perk J, De Backer G, Gohlke H et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012; 33:1635-701. http://www.ncbi.nlm.nih.gov/pubmed/22555213?dopt=AbstractPlus

542. Marik PE, Varon J. Hypertensive crises: challenges and management. Chest. 2007; 131:1949-62. http://www.ncbi.nlm.nih.gov/pubmed/17565029?dopt=AbstractPlus

702. Soukoulis V, Boden WE, Smith SC et al. Nonantithrombotic medical options in acute coronary syndromes: old agents and new lines on the horizon. Circ Res. 2014; 114:1944-58. http://www.ncbi.nlm.nih.gov/pubmed/24902977?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=4083844&blobtype=pdf

1100. Amsterdam EA, Wenger NK, Brindis RG et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014; 130:e344-426. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=4676081&blobtype=pdf

1101. Fihn SD, Gardin JM, Abrams J et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012; 126:e354-471.

1150. Flynn JT, Kaelber DC, Baker-Smith CM et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics. 2017; 140 http://www.ncbi.nlm.nih.gov/pubmed/28827377?dopt=AbstractPlus

1200. Whelton PK, Carey RM, Aronow WS et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017; http://www.ncbi.nlm.nih.gov/pubmed/29146535?dopt=AbstractPlus

1201. Bakris G, Sorrentino M. Redefining hypertension - assessing the new blood-pressure guidelines. N Engl J Med. 2018; 378:497-499. http://www.ncbi.nlm.nih.gov/pubmed/29341841?dopt=AbstractPlus

1202. Carey RM, Whelton PK, 2017 ACC/AHA Hypertension Guideline Writing Committee. Prevention, detection, evaluation, and management of high blood pressure in adults: synopsis of the 2017 American College of Cardiology/American Heart Association hypertension guideline. Ann Intern Med. 2018; 168:351-358. http://www.ncbi.nlm.nih.gov/pubmed/29357392?dopt=AbstractPlus

1207. Burnier M, Oparil S, Narkiewicz K et al. New 2017 American Heart Association and American College of Cardiology guideline for hypertension in the adults: major paradigm shifts, but will they help to fight against the hypertension disease burden?. Blood Press. 2018; 27:62-65. http://www.ncbi.nlm.nih.gov/pubmed/29447001?dopt=AbstractPlus

1209. Qaseem A, Wilt TJ, Rich R et al. Pharmacologic treatment of hypertension in adults aged 60 years or older to higher versus lower blood pressure targets: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2017; 166:430-437. http://www.ncbi.nlm.nih.gov/pubmed/28135725?dopt=AbstractPlus

1210. SPRINT Research Group, Wright JT, Williamson JD et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015; 373:2103-16. http://www.ncbi.nlm.nih.gov/pubmed/26551272?dopt=AbstractPlus

1213. Reboussin DM, Allen NB, Griswold ME et al. Systematic review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017; http://www.ncbi.nlm.nih.gov/pubmed/29146534?dopt=AbstractPlus

1216. Taler SJ. Initial treatment of hypertension. N Engl J Med. 2018; 378:636-644. http://www.ncbi.nlm.nih.gov/pubmed/29443671?dopt=AbstractPlus

1220. Cifu AS, Davis AM. Prevention, detection, evaluation, and management of high blood pressure in adults. JAMA. 2017; 318:2132-2134. http://www.ncbi.nlm.nih.gov/pubmed/29159416?dopt=AbstractPlus

1222. Bell KJL, Doust J, Glasziou P. Incremental benefits and harms of the 2017 American College of Cardiology/American Heart Association high blood pressure guideline. JAMA Intern Med. 2018; 178:755-7. http://www.ncbi.nlm.nih.gov/pubmed/29710197?dopt=AbstractPlus

1223. LeFevre M. ACC/AHA hypertension guideline: what is new? what do we do?. Am Fam Physician. 2018; 97(6):372-3. http://www.ncbi.nlm.nih.gov/pubmed/29671534%20?dopt=AbstractPlus

1224. Brett AS. New hypertension guideline is released. From NEJM Journal Watch website. Accessed 2018 Jun 18. https://www.jwatch.org/na45778/2017/12/28/nejm-journal-watch-general-medicine-year-review-2017

1229. Ioannidis JPA. Diagnosis and treatment of hypertension in the 2017 ACC/AHA guidelines and in the real world. JAMA. 2018; 319(2):115-6. http://www.ncbi.nlm.nih.gov/pubmed/29242891?dopt=AbstractPlus

a. AHFS drug information 2018. McEvoy GK, ed. Nifedipine. Bethesda, MD: American Society of Hospital Pharmacists; 2018:.

Hide